0001845459--12-312023Q2falsetrue0042903754290375000000000042903754290375P45D0.200001845459us-gaap:CommonStockMemberus-gaap:IPOMember2023-06-3000018454592023-05-220001845459gfor:PublicWarrantsMemberus-gaap:CommonStockMember2023-05-220001845459us-gaap:CommonStockMember2023-05-220001845459gfor:CommonClassaSubjectToRedemptionMember2023-06-300001845459gfor:CommonClassaSubjectToRedemptionMember2022-12-310001845459gfor:FounderSharesMembergfor:SponsorMember2021-02-132021-02-130001845459us-gaap:WarrantMember2023-05-152023-05-150001845459us-gaap:RetainedEarningsMember2023-06-300001845459us-gaap:RetainedEarningsMember2023-03-3100018454592023-03-310001845459us-gaap:RetainedEarningsMember2022-12-310001845459us-gaap:RetainedEarningsMember2022-06-300001845459us-gaap:RetainedEarningsMember2022-03-3100018454592022-03-310001845459us-gaap:RetainedEarningsMember2021-12-310001845459us-gaap:FairValueInputsLevel3Membergfor:PrivatePlacementWarrantsMember2023-06-300001845459us-gaap:FairValueInputsLevel3Membergfor:PrivatePlacementWarrantsMember2022-12-310001845459us-gaap:CommonStockMember2023-06-300001845459us-gaap:CommonStockMember2023-03-310001845459us-gaap:CommonStockMember2022-12-310001845459us-gaap:CommonStockMember2022-06-300001845459us-gaap:CommonStockMember2022-03-310001845459us-gaap:CommonStockMember2021-12-310001845459us-gaap:IPOMember2023-06-300001845459gfor:RelatedPartyLoansMembergfor:SponsorMember2021-01-292021-01-290001845459gfor:PrivatePlacementsMembergfor:SponsorMemberus-gaap:PrivatePlacementMember2021-05-252021-05-250001845459gfor:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-05-252021-05-250001845459gfor:PublicWarrantsMemberus-gaap:CommonStockMember2023-05-222023-05-220001845459us-gaap:CommonStockMember2023-05-222023-05-2200018454592023-05-222023-05-220001845459gfor:CommonStockSubjectToPossibleRedemptionMember2023-04-012023-06-300001845459gfor:AdministrativeSupportAgreementMember2023-06-300001845459gfor:AdministrativeSupportAgreementMember2022-12-310001845459gfor:OtherRelatedPartyTransactionsMember2023-06-300001845459gfor:OtherRelatedPartyTransactionsMember2022-12-310001845459us-gaap:RetainedEarningsMember2023-04-012023-06-300001845459us-gaap:RetainedEarningsMember2023-01-012023-03-3100018454592023-01-012023-03-310001845459us-gaap:RetainedEarningsMember2022-04-012022-06-300001845459us-gaap:RetainedEarningsMember2022-01-012022-03-3100018454592022-01-012022-03-310001845459us-gaap:FairValueInputsLevel3Member2023-06-300001845459us-gaap:FairValueInputsLevel3Member2023-03-310001845459us-gaap:FairValueInputsLevel3Member2022-12-310001845459us-gaap:FairValueInputsLevel3Member2022-06-300001845459us-gaap:FairValueInputsLevel3Member2022-03-310001845459us-gaap:FairValueInputsLevel3Member2021-12-310001845459us-gaap:FairValueInputsLevel3Member2023-04-012023-06-300001845459us-gaap:FairValueInputsLevel3Member2023-01-012023-03-310001845459us-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001845459us-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2023-06-300001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-06-300001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2023-06-300001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2023-06-300001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMember2023-06-300001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2023-06-300001845459us-gaap:FairValueInputsLevel3Membergfor:MeasurementInputProbabilityOfCompletionOfBusinessCombinationMember2023-06-300001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2022-12-310001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-12-310001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2022-12-310001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2022-12-310001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMember2022-12-310001845459us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2022-12-310001845459us-gaap:FairValueInputsLevel3Membergfor:MeasurementInputProbabilityOfCompletionOfBusinessCombinationMember2022-12-310001845459gfor:OtherRelatedPartyTransactionsMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001845459gfor:OtherRelatedPartyTransactionsMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001845459gfor:FounderSharesMembergfor:SponsorMember2021-06-020001845459gfor:CommonStockNotSubjectToPossibleRedemptionMember2023-06-300001845459gfor:CommonStockNotSubjectToPossibleRedemptionMember2022-12-310001845459gfor:PrivatePlacementWarrantsMember2022-12-310001845459gfor:PrivatePlacementsMembergfor:SponsorMembergfor:PrivatePlacementTwoMember2021-05-250001845459gfor:PublicWarrantsMemberus-gaap:IPOMember2021-05-2500018454592021-12-310001845459us-gaap:DemandDepositsMember2023-06-300001845459us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-12-310001845459us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310001845459us-gaap:USTreasurySecuritiesMember2022-12-310001845459us-gaap:DemandDepositsMember2022-12-310001845459gfor:GSpacManagementLlcMembergfor:AdministrativeSupportAgreementMemberus-gaap:RelatedPartyMember2021-05-202021-05-200001845459us-gaap:CommonStockMemberus-gaap:IPOMember2023-01-012023-06-300001845459gfor:CommonStockSubjectToPossibleRedemptionMember2023-01-012023-03-310001845459gfor:CommonStockSubjectToPossibleRedemptionMember2022-01-012022-12-310001845459gfor:PublicWarrantsMember2023-06-3000018454592022-05-160001845459us-gaap:OverAllotmentOptionMember2021-06-020001845459us-gaap:IPOMember2021-05-250001845459gfor:FounderSharesMembergfor:SponsorMember2023-01-012023-06-300001845459gfor:GSpacManagementLlcMembergfor:AdministrativeSupportAgreementMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001845459gfor:RelatedPartyLoansMembergfor:SponsorMember2023-01-012023-06-3000018454592022-01-012022-12-310001845459gfor:FounderSharesMembergfor:SponsorMember2021-04-082021-04-080001845459gfor:SponsorMember2023-01-012023-06-300001845459gfor:PublicWarrantsMemberus-gaap:IPOMember2021-05-252021-05-250001845459gfor:AlexandraLebenthalMembergfor:FounderSharesMembergfor:SponsorMember2021-07-142021-07-140001845459gfor:IndependentDirectorsMembergfor:FounderSharesMembergfor:SponsorMember2021-04-082021-04-080001845459gfor:FounderSharesMembergfor:SponsorMember2021-04-080001845459gfor:FounderSharesMembergfor:SponsorMember2021-06-022021-06-020001845459us-gaap:OverAllotmentOptionMember2021-05-252021-05-250001845459gfor:RelatedPartyLoansMembergfor:SponsorMember2021-01-2900018454592022-05-162022-05-1600018454592023-04-012023-06-3000018454592022-06-300001845459gfor:OtherRelatedPartyTransactionsMembersrt:ChiefFinancialOfficerMember2022-12-212022-12-210001845459gfor:OtherRelatedPartyTransactionsMembersrt:OfficerMember2022-05-062022-05-060001845459gfor:CommonStockSubjectToPossibleRedemptionMember2023-06-300001845459gfor:CommonStockSubjectToPossibleRedemptionMember2023-03-310001845459gfor:CommonStockSubjectToPossibleRedemptionMember2022-12-310001845459gfor:CommonStockSubjectToPossibleRedemptionMember2021-12-3100018454592022-12-3100018454592023-06-300001845459gfor:CommonClassaSubjectToRedemptionMember2023-01-012023-06-300001845459gfor:PublicWarrantsMember2023-01-012023-06-300001845459gfor:RelatedPartyLoansMembergfor:SponsorMember2023-06-300001845459gfor:SponsorMemberus-gaap:ConvertibleDebtMember2023-05-150001845459gfor:PrivatePlacementsMembergfor:SponsorMembergfor:PrivatePlacementTwoMember2021-06-020001845459gfor:PrivatePlacementsMembergfor:SponsorMember2021-06-020001845459gfor:AdditionalPrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-06-020001845459gfor:PrivatePlacementsMembergfor:SponsorMemberus-gaap:PrivatePlacementMember2021-05-250001845459gfor:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-05-250001845459gfor:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Membergfor:PublicWarrantsMember2023-01-012023-06-3000018454592022-04-012022-06-3000018454592022-01-012022-06-300001845459us-gaap:OverAllotmentOptionMember2021-06-022021-06-020001845459us-gaap:IPOMember2021-05-252021-05-250001845459gfor:VendorAgreementMember2023-05-082023-05-080001845459gfor:GSpacManagementLlcMembergfor:AdministrativeSupportAgreementMemberus-gaap:RelatedPartyMember2023-01-012023-03-310001845459srt:MinimumMembergfor:VendorAgreementMember2023-05-082023-05-080001845459srt:MaximumMembergfor:VendorAgreementMember2023-05-082023-05-080001845459gfor:PrivatePlacementsMembergfor:SponsorMembergfor:PrivatePlacementTwoMember2021-06-022021-06-020001845459gfor:AdditionalPrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-06-022021-06-020001845459us-gaap:CommonStockMember2023-01-012023-06-300001845459gfor:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember2023-01-012023-06-300001845459gfor:UnitsEachConsistingOfOneShareOfCommonStockAndOneFifthOfOneRedeemableWarrantMember2023-01-012023-06-3000018454592023-08-1400018454592023-01-012023-06-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesgfor:Dgfor:Votegfor:itemxbrli:puregfor:Y

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to

GRAF ACQUISITION CORP. IV

(Exact name of registrant as specified in its charter)

Delaware

    

001-40427

    

86-2191918

(State or other jurisdiction of

incorporation or organization)

(Commission
File Number)

 

(I.R.S. Employer

Identification Number) 

1790 Hughes Landing Blvd., Suite 400

The Woodlands, Texas

    

77380

(Address of principal executive offices)

 

(Zip Code)

(346) 442-0819 (Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Units, each consisting of one share of common stock and one-fifth of one redeemable warrant

 

GFOR.U

 

The New York Stock Exchange

Common stock, par value $0.0001 per share

 

GFOR

 

The New York Stock Exchange

Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share

 

GFOR WS

 

The New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 

Accelerated filer

 Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

As of August 14, 2023, 10,373,875 shares of common stock, par value $0.0001, were issued and outstanding.

GRAF ACQUISITION CORP. IV

Quarterly Report on Form 10-Q

Table of Contents

Page No.

PART I. FINANCIAL INFORMATION

Item 1.

Unaudited Condensed Consolidated Financial Statements

1

Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022

1

Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022

2

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the Three and Six Months Ended June 30, 2023 and 2022

3

Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022

4

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

26

Item 4.

Controls and Procedures

26

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

27

Item 1A.

Risk Factors

27

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

27

Item 4.

Mine Safety Disclosures

27

Item 5.

Other Information

27

Item 6.

Exhibits

28

SIGNATURE

29

PART I - FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated Financial Statements

GRAF ACQUISITION CORP. IV

CONDENSED CONSOLIDATED BALANCE SHEETS

    

June 30, 2023

    

December 31, 2022

(Unaudited)

Assets:

Current assets:

Cash

$

41,459

$

635,155

Prepaid expenses

34,179

 

242,752

Total current assets

75,638

877,907

Cash and investments held in Trust Account

63,529,895

    

173,488,201

Total Assets

$

63,605,533

$

174,366,108

Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Deficit:

Current liabilities:

 

Accounts payable

$

163,344

$

177,157

Franchise tax payable

66,255

42,705

Accrued expenses

5,050,540

2,444,352

Due to related party

32,809

 

Income tax payable

572,146

181,374

Convertible promissory note - related party

416,710

Total current liabilities

6,301,804

2,845,588

Derivative warrant liability

944,310

424,940

Deferred underwriting commissions in connection with the initial public offering

2,102,284

2,102,284

Total Liabilities

9,348,398

5,372,812

Commitments and Contingencies

 

 

Common stock subject to possible redemption; 6,083,500 and 17,161,500 shares at redemption value of approximately $10.32 and $10.09 per share as of June 30, 2023 and December 31, 2022, respectively

62,796,284

173,164,122

Stockholders’ Deficit:

Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding as of June 30, 2023 and December 31, 2022

Common stock, $0.0001 par value; 400,000,000 shares authorized; 4,290,375 shares issued and outstanding (excluding 6,083,500 and 17,161,500 shares subject to possible redemption) as of June 30, 2023 and December 31, 2022, respectively

429

 

429

Additional paid-in capital

 

Accumulated deficit

(8,539,578)

 

(4,171,255)

Total stockholders’ deficit

(8,539,149)

(4,170,826)

Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Deficit

$

63,605,533

$

174,366,108

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

GRAF ACQUISITION CORP. IV

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended

For the Six Months Ended

June 30, 

June 30,

    

2023

    

2022

    

2023

    

2022

General and administrative expenses

$

2,581,577

$

874,637

$

3,441,419

$

1,512,778

General and administrative expenses - related party

45,000

45,000

90,000

90,000

Franchise tax expenses

50,000

49,315

100,000

98,082

Loss from operations

(2,676,577)

(968,952)

(3,631,419)

(1,700,860)

Other income (expense)

Change in fair value of derivative warrant liability

(283,300)

1,605,330

(519,370)

4,296,600

Gain on settlement of deferred underwriting commissions

179,595

179,595

Income from investments held in Trust Account

1,415,607

124,764

3,389,390

168,792

Other income (expense)

1,132,307

1,909,689

2,870,020

4,644,987

Net (loss) income before income tax

(1,544,270)

940,737

(761,399)

2,944,127

Income tax (expense) benefit

(286,778)

15,402

(690,772)

15,402

Net (loss) income

$

(1,831,048)

$

956,139

$

(1,452,171)

$

2,959,529

 

 

 

Weighted average shares outstanding of common stock, basic

 

16,825,897

21,451,875

 

19,126,107

 

21,451,875

Basic and diluted net (loss) income per share, common stock

$

(0.11)

$

0.04

$

(0.08)

$

0.14

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

GRAF ACQUISITION CORP. IV

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023

Total

Common Stock

Additional Paid-In

Accumulated

Stockholders’

    

Shares

    

Amount

    

Capital

    

Deficit

    

Deficit

Balance - December 31, 2022

4,290,375

$

429

$

$

(4,171,255)

$

(4,170,826)

 

Net income

378,877

378,877

Adjustment for accretion of common stock subject to possible redemption amount

(1,507,323)

(1,507,323)

Balance - March 31, 2023 (Unaudited)

4,290,375

429

(5,299,701)

(5,299,272)

Net loss

(1,831,048)

(1,831,048)

Adjustment for accretion of common stock subject to possible redemption amount

(1,408,829)

(1,408,829)

Balance - June 30, 2023 (Unaudited)

4,290,375

$

429

$

$

(8,539,578)

$

(8,539,149)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022

Total

    

Common Stock

Additional Paid-In

Accumulated

    

Stockholders’

    

Shares

    

Amount

    

Capital

    

Deficit

    

Deficit

Balance - December 31, 2021

4,290,375

$

429

$

$

(10,895,130)

$

(10,894,701)

 

 

 

 

 

Net income

2,003,390

2,003,390

Balance - March 31, 2022 (Unaudited)

4,290,375

429

(8,891,740)

(8,891,311)

Net income

956,139

956,139

Adjustment for accretion of common stock subject to possible redemption amount

3,724,646

3,724,646

Balance - June 30, 2022 (Unaudited)

4,290,375

$

429

$

$

(4,210,955)

$

(4,210,526)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

GRAF ACQUISITION CORP. IV

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six Months Ended

June 30,

    

2023

    

2022

Cash Flows from Operating Activities:

  

Net (loss) income

$

(1,452,171)

$

2,959,529

Adjustments to reconcile net (loss) income to net cash used in operating activities:

 

Change in fair value of derivative warrant liability

519,370

(4,296,600)

Gain on settlement of deferred underwriting commissions

(179,595)

Income from investments held in Trust Account

(3,389,390)

(168,792)

Change in operating assets and liabilities:

Prepaid expenses

208,573

288,199

Prepaid expenses - related party

(13,173)

Accounts payable

(13,813)

79,438

Franchise tax payable

23,550

(56,214)

Income tax payable

390,772

(15,402)

Due to related party

32,809

Accrued expenses

2,618,655

940,161

Net cash used in operating activities

(1,061,645)

(462,449)

 

Cash Flows from Investing Activities:

Investment of cash into Trust Account

(330,000)

Cash withdrawals from Trust Account to pay for taxes

381,239

 

Cash withdrawn from Trust Account in connection with redemption

113,296,457

Net cash provided by investing activities

113,347,696

Cash Flows from Financing Activities:

Proceeds from convertible promissory note - related party

416,710

Redemption of common stock

(113,296,457)

Net cash used in financing activities

(112,879,747)

Net change in cash

(593,696)

(462,449)

Cash – beginning of the period

635,155

1,722,506

Cash – end of the period

$

41,459

$

1,260,057

Supplementary cash flow information:

Cash paid for income taxes

$

300,000

$

Supplemental disclosure of noncash activities:

Extinguishment of accrued expenses related to offering costs

$

13,924

$

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

Note 1—Description of Organization and Business Operations

Graf Acquisition Corp. IV (“Graf”) is a newly organized blank check company incorporated in Delaware and formed for the purpose of effecting into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.

On December 9, 2021, Graf incorporated Austria Merger Sub, Inc. (“Merger Sub”), a Delaware corporation. Graf and its subsidiary are collectively referred to as the “Company.”

On April 14, 2023, Graf entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merger Sub and NKGen Biotech, Inc., a Delaware corporation (“NKGen”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into NKGen (the “Merger”), with NKGen surviving the Merger in accordance with the Delaware General Corporation Law as a wholly owned subsidiary of Graf (the Merger, together with the other transactions contemplated by the Merger Agreement and the related ancillary agreements, the “Business Combination”).

As of June 30, 2023, the Company had not yet commenced operations. All activity for the period from January 28, 2021 (inception) through June 30, 2023, relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on the proceeds derived from the Initial Public Offering.

The Company’s sponsor is Graf Acquisition Partners IV LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on May 20, 2021. On May 25, 2021, the Company consummated its Initial Public Offering of 15,000,000 units (the “Units” and, with respect to the common stock included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $150.0 million, and incurring offering costs of approximately $8.8 million, of which approximately $5.3 million was for deferred underwriting commissions (see Note 5). The Company granted the underwriter a 45-day option to purchase up to an additional 2,250,000 Units at the Initial Public Offering price to cover over-allotments. On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased 2,161,500 additional Units (the “Additional Units”), generating gross proceeds of approximately $21.6 million (the “Over-Allotment”). The Company incurred additional offering costs of approximately $1.2 million in connection with the Over-Allotment (of which approximately $757,000 was for deferred underwriting fees).

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 4,433,333 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $6.7 million (see Note 4). Simultaneously with the closing of the Over-Allotment on June 2, 2021, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 288,200 Private Placement Warrants at $1.50 per Private Placement Warrant (the “Additional Private Placement Warrants”), generating additional gross proceeds of approximately $432,000.

Upon the closing of the Initial Public Offering, Over-Allotment, and Private Placement, $171.6 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering, Over-Allotment and of the Private Placement Warrants in the Private Placement were placed in a trust account (“Trust Account”) in the United States maintained by Continental Stock Transfer & Trust Company, as trustee, and has been invested only in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, or the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.

5

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide the holders of Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially at $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). These Public Shares were recorded at a redemption value and classified as temporary equity, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Charter”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Founder Shares (as defined in Note 4) prior to this Initial Public Offering (the “Initial Stockholders”) agreed to vote their Founder Shares and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Stockholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. In addition, the Company agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor.

Notwithstanding the foregoing, the Charter provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the shares of common stock sold in the Initial Public Offering, without the prior consent of the Company.

The Company’s Sponsor, executive officers, and directors have agreed not to propose an amendment to the Charter that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.

6

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

If a Business Combination has not been consummated by September 29, 2023 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

On May 22, 2023, the Company held a special meeting of stockholders (the "Meeting"), pursuant to which the Company's stockholders approved a proposal to amend the Charter (the "Charter Amendment") to (i) provide the Company with the right to extend the date by which the Company must consummate its initial business combination (the "Extension"), from May 25, 2023 to September 29, 2023 (the "Extended Date"), and to and (ii) permit the Company's board of directors, in its sole discretion, to elect to wind up the Company's operations on an earlier date than the Extended Date as determined by the board of directors and included in a public announcement. In addition, on May 22, 2023, the Company filed the Charter Amendment with the Secretary of State of the State of Delaware. In addition, in connection with the Extension, the Company shall deposit into the Trust Account $0.03 per Public Share of common stock that is not redeemed, up to $165,000, for each calendar month (or pro rata portion thereof if less than a full month), until the earlier to occur of (i) September 29, 2023, (ii) the closing of the Business Combination and (iii) the Company’s liquidation.

In connection with the vote to approve the Extension Amendment Proposal, the holders of 11,078,000 shares of common stock properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.227 per share, for an aggregate redemption amount of approximately $113.3 million.

The Initial Stockholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account.

The Company will seek to have all third parties (except the Company’s independent registered public accounting firm) and any prospective target businesses enter into valid and enforceable agreements with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account. Nevertheless, there is no guarantee that vendors, service providers and prospective target businesses will execute such agreements. The Company’s insiders agreed that they will be jointly and severally liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per Public Share, except as to any claims by a third party who executed an agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. However, the Company’s insiders may not be able to satisfy their indemnification obligations. Moreover, the Company’s insiders will not be liable to the Public Stockholders and instead will only have liability to the Company.

Liquidity and Going Concern

As of June 30, 2023, the Company had approximately $41,000 in its operating bank account and working capital deficit of approximately $6.2 million.

The Company’s liquidity needs through June 30, 2023 were satisfied through a payment of $25,000 from the Sponsor to purchase the Founder Shares (as defined in Note 4), the loan of approximately $67,000 from the Sponsor under the Note (as defined in Note 4 to the unaudited condensed consolidated financial statements), and the proceeds from the consummation of the Private Placement not held in the Trust Account. The Company repaid the Note in full on May 26, 2021. In addition, in order to finance transaction costs

7

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors, may, but are not obligated to, provide Working Capital Loans (as defined in Note 4 to the unaudited condensed consolidated financial statements). As of June 30, 2023, and December 31, 2022, there were $416,710 and $0 amounts outstanding under any Working Capital Loans, respectively, borrowed under the Convertible Promissory Note (defined in Note 4).

In connection with the Company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the liquidity condition, the mandatory liquidation and subsequent dissolution that will be required if the Company does not complete a business combination before September 29, 2023 (unless extended in accordance with the amended and restated certificate of incorporation) raises substantial doubt about the Company’s ability to continue as a going concern. Although management expects that it will be able to raise additional capital to support its planned activities and complete a business combination on or prior to September 29, 2023 (unless extended in accordance with the amended and restated certificate of incorporation), it is uncertain whether it will be able to do so. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after September 29, 2023 (unless extended in accordance with the amended and restated certificate of incorporation). The unaudited condensed consolidated financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

Note 2—Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these condensed financial statements as they are not required for interim financial statements under GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the period presented. Operating results for the three and six months ended June 30, 2023, and since inception are not necessarily indicative of the results that may be expected through December 31, 2023, or any future period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2023.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

8

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of income and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2023, and December 31, 2022.

Cash and investments Held in the Trust Account

The Company’s portfolio of investments is comprised of cash and U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. Gains and losses resulting from the change in fair value of these securities are included in income on investments held in the Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB Topic ASC 820, “Fair Value Measurements,” equals or approximates the carrying amounts represented in the condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liabilities.

9

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Derivative Warrant Liability

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company will evaluate its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

The Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the carrying value of the instruments to fair value at each reporting period until they are exercised. The fair value of the Private Placement Warrants as of June 30, 2023, and December 31, 2022, is determined using Black-Scholes option pricing model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Offering Costs Associated with the Initial Public Offering

Offering costs consist of legal, underwriting fees, accounting, and other costs incurred through the condensed consolidated balance sheet date that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liability will be expensed as incurred, presented as non-operating expenses in the condensed statements of operations. Offering costs associated with the Public Shares issued were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as liability instruments and is measured at fair value. Conditionally redeemable common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain

10

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, June 30, 2023 and December 31, 2022, 6,083,500 and 17,161,500 shares of common stock subject to possible redemption at the redemption amount were presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed consolidated balance sheets, respectively.

Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering (including exercise of the over-allotment option), the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2023 and December 31, 2022, the Company had full valuation allowance against the deferred tax assets.

ASC 740 prescribes a recognition threshold and a measurement attribute for the unaudited condensed consolidated financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2023 and December 31, 2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of June 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.

Net (Loss) Income per Share of Common Stock

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net (loss) income per common stock is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding during the period.

The calculation of diluted net (loss) income per common stock does not consider the effect of the warrants issued in connection with the Initial Public Offering (including exercise of the over-allotment option) and the Private Placement to purchase an aggregate of 8,153,833 shares of common stock in the calculation of diluted (loss) income per common stock, because their exercise is contingent upon future events. As a result, diluted net (loss) income per common stock is the same as basic net (loss) income per common stock for the three and six months ended June 30, 2023 and 2022. Accretion associated with the redeemable common stock is excluded from earnings per share as the redemption value approximates fair value.

11

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

Recent Accounting Pronouncements

In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820, “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the unaudited condensed consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.

Note 3—Initial Public Offering

On May 25, 2021, the Company consummated its Initial Public Offering of 15,000,000 Units, at $10.00 per Unit, generating gross proceeds of $150.0 million, and incurring offering costs of approximately $8.8 million, of which approximately $5.3 million was for deferred underwriting commissions. The Company granted the underwriters a 45-day option to purchase up to 2,250,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased 2,161,500 additional Units (the “Additional Units”), generating gross proceeds of approximately $21.6 million (the “Over-Allotment”). The Company incurred additional offering costs of approximately $1.2 million in connection with the Over-Allotment (of which approximately $0.8 million was for deferred underwriting fees). On May 16, 2022, one of the underwriters waived their deferred fee of approximately $3.9 million.

Each Unit consists of one share of common stock, and one-fifth of one redeemable warrant (“Public Warrant”). Each whole Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 7).

Note 4—Related Party Transactions

Founder Shares

On February 13, 2021, Graf Acquisition Partners LLC (“Graf LLC”) paid an aggregate of $25,000 for certain offering costs on behalf of the Company in exchange for issuance of 4,312,500 shares of common stock (the “Founder Shares”). On April 2, 2021, Graf LLC transferred all of its Founder shares to the Sponsor. On April 8, 2021, the Sponsor transferred 20,000 Founder Shares to each of the Company’s independent directors, resulting in the Sponsor holding 4,252,500 Founder Shares. The holders of the Founder Shares agreed to forfeit up to an aggregate of 562,500 Founder Shares, on a pro rata basis, to the extent that the option to purchase additional units is not exercised in full by the underwriters, so that the Founder Shares will represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters partially exercised their over-allotment option on June 2, 2021, and forfeited the remaining option; and, as a result, an aggregate of 22,125 Founder Shares were forfeited, resulting in 4,290,375 Founder Shares outstanding. On July 14, 2021, the Sponsor transferred 20,000 Founder Shares to Alexandra Lebenthal in connection with her appointment to the Company’s board of directors.

The Initial Stockholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 120 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property.

12

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

Private Placement

Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 4,433,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $6.7 million. Simultaneously with the closing of the Over-Allotment on June 2, 2021, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 288,200 Private Placement Warrants at $1.50 per Private Placement Warrant (the “Additional Private Placement Warrants”), generating additional gross proceeds of approximately $0.4 million.

Each whole Private Placement Warrant entitles the holder thereof to purchase one common stock at an exercise price of $11.50 per full share. A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees (see Note 8).

Related Party Loans

On January 29, 2021, the Sponsor agreed to loan the Company up to $150,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note was non-interest bearing, unsecured and due upon the consummation of the Initial Public Offering. The Company had borrowed approximately $70,000 under the Note. The Note was paid back in full on May 26, 2021. Subsequent to the repayment, the facility was no longer available to the Company.

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or any of the Company’s officers or directors may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion (the “Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the initial Business Combination, without interest. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used for such repayment. Up to $1,500,000 of such Working Capital Loans may be convertible into additional warrants at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans.

In connection with the Extension and advances the Sponsor may make in the future to the Company for working capital expenses, on May 15, 2023, the Company issued a convertible promissory note to the Sponsor with a principal amount up to $1,500,000 (the "Convertible Promissory Note"). The Convertible Promissory Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Company's initial business combination, or (b) the date of the Company's liquidation. If the Company does not consummate an initial business combination by the Extended Date, the Convertible Promissory Note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. Subject to the terms and conditions of the Merger Agreement, dated as of April 14, 2023, by and among Graf, Merger Sub and NKGen, upon maturity, the outstanding principal of the Note may be converted into warrants, at a price of $1.50 per warrant, at the option of the Sponsor. Such warrants will have terms identical to the warrants issued to the Sponsor in a private placement that closed simultaneously with the Company's initial public offering. Any drawdowns in connection with the Convertible Promissory Note are subject to unanimous written consent of the Company's board of directors and the consent of the Sponsor. In no event shall the quantity of warrants issued exceed one million (1,000,000) warrants. As of June 30, 2023, and December 31, 2022, the Company had $416,710 and $0, respectively, borrowings under the Convertible Promissory Note.

Administrative Services Agreement

On May 20, 2021, the Company entered into an agreement that provided that, commencing on the date that the Company’s securities were first listed on the NYSE through the earlier of consummation of the initial Business Combination and the liquidation, the Company agreed to pay G-SPAC Management LLC, an affiliate of the Sponsor, $15,000 per month for office space, utilities, secretarial, administrative and support services provided to the Company and members of the management team. For the three and six months ended June 30, 2023, the Company incurred expenses of approximately $45,000 and $90,000 under this agreement, respectively.

13

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

As of June 30, 2023 and December 31, 2022, there was no outstanding balance on the unaudited condensed consolidated balance sheets for these expenses.

Other Related Party Transactions

On December 21, 2022, at a special meeting of stockholders, the Company’s stockholders approved the payment of compensation of $16,667 per month base to the Company’s full-time Chief Financial Officer plus any related taxes (including, without limitation, Medicare and social security), governmental payments and health care benefits, for services rendered to the Company as an employee, contractor or otherwise from May 6, 2022 (retroactive) through the Company’s closing of a Business Combination. The stockholders also approved the payment of up to $6,000 per month in aggregate for health care benefits for the officers of the Company who are not otherwise receiving compensation from the Company. For the three and six months ended June 30, 2023, the Company incurred expenses of approximately $81,000 and $170,000 under this agreement, respectively. For the three and six months ended June 30, 2022, the Company did not incur expenses under this agreement. As of June 30, 2023 and December 31, 2022, there was an outstanding balance of $32,809 and $0 reported as due to related party for these expenses on the unaudited condensed consolidated balance sheets, respectively.

In addition, the Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, officers or directors, or their affiliates. Any such payments prior to an initial Business Combination will be made from funds held outside the Trust Account. As of June 30, 2023 and December 31, 2022, there was an outstanding balance of $6,652 and $0, respectively, reported as accrued expenses for reimbursable expenses on the unaudited condensed consolidated balance sheets.

Note 5—Commitments and Contingencies

Registration and Stockholder Rights

The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) were entitled to registration rights pursuant to a registration rights agreement signed upon the effective date of the Initial Public Offering. These holders were entitled to make up to three demands, excluding short form registration demands, that the Company registered such securities for sale under the Securities Act. In addition, these holders will have “piggyback” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 2,250,000 additional Units less the underwriting discounts and commissions. On June 2, 2021, the underwriters partially exercised the over-allotment option. On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased an additional 2,161,500 Units.

The underwriters were entitled to an underwriting discount of $0.20 per unit, or $3.4 million in the aggregate, paid upon the closing of the Initial Public Offering ($3.0 million) and Over-Allotment (approximately $0.4 million). In addition, $0.35 per unit, or approximately $6.0 million in the aggregate was payable to the underwriters for deferred underwriting commissions (approximately $5.25 million related to the Initial Public Offering and $0.8 million related to the Over-Allotment). The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. On May 16, 2022, J.P. Morgan Securities LLC (“JPM”), one of the representatives of the underwriters of the Company’s Initial Public Offering, waived their deferred underwriting fee that accrued from JPM’s participation in the Initial Public Offering of approximately $3.9 million. The Company derecognized approximately $3.7 million of the commissions waiver allocated to Public Shares to the carrying value of the common stock subject to possible redemption and the remaining balance of approximately $180,000 as a gain from extinguishment of deferred underwriting commissions allocated to derivative warrant liability.

14

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

Vendor Agreement

On May 8, 2023, the Company entered into an agreement with a vendor for capital market advisement services related to the Business Combination Agreement. The agreement calls for the vendor to receive an advisory fee payable in cash or a combination of cash and common stock of the surviving entity following the Business Combination. The advisory fee payable is as follows (i) $2,000,000 in cash and $2,000,000 in common stock if the total capital raised involved in the Business Combination is less than $20,000,000 or (ii) $2,500,000 in cash and $2,000,000 in common stock if the total capital raised involved in the Business Combination is greater than or equal to $20,000,000 and less than $40,000,000 or (iii) 4,000,000 in cash and $1,000,000 in common stock if the total capital raised involved in the Business Combination is greater than or equal to $40,000,000 and less than $50,000,000 or (iv) 5,000,000 in cash if the total capital raised involved in the Business Combination is greater than or equal to $50,000,000. The Company is also required to reimburse the vendor for out-of-pocket expenses which are capped at an aggregate of $200,000, of which approximately $4,500 has been accrued as of June 30, 2023 and included in accrued expenses on the unaudited condensed balance sheets.

Risks and Uncertainties

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy is not determinable as of the date of these unaudited condensed consolidated financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed consolidated financial statements.

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (the “IR Act”), which, among other things, imposes a new 1% U.S. federal excise tax on certain repurchases of stock by “covered corporations” (which include publicly traded domestic (i.e., U.S.) corporations) beginning in 2023, with certain exceptions (the “Excise Tax”). The Excise Tax is imposed on the repurchasing corporation itself, not its stockholders from which the stock is repurchased. Because the Company is a Delaware corporation and its securities are trading on the NYSE, the Company is a “covered corporation” for this purpose. The amount of the Excise Tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the Excise Tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the Excise Tax.

On December 27, 2022, the Treasury published Notice 2023-2, which provided clarification on some aspects of the application of the Excise Tax, including with respect to some transactions in which special purpose acquisition companies typically engage. In the notice, the Treasury appears to have intended to exempt from the excise tax any distributions, including those that occur in connection with redemptions, by a corporation in the same year it completely liquidates, but the guidance is not clearly drafted and arguably could be interpreted to have a narrower application. Consequently, a substantial risk remains that any redemptions would be subject to the Excise Tax, including in circumstances where the Company either engages in a business combination in 2023 in which the Company does not issue shares sufficient to offset the earlier redemptions or liquidates later in 2023.

Because the application of the Excise Tax is not entirely clear, any redemption or other repurchase effected by the Company, in connection with a business combination, extension vote or otherwise, may be subject to the Excise Tax. Whether and to what extent the Company would be subject to the Excise Tax on a redemption of shares of common stock or other stock issued by the Company would depend on a number of factors, including (i) whether the redemption is treated as a repurchase of stock for purposes of the Excise Tax, (ii) the fair market value of the redemption treated as a repurchase of stock in connection with the initial business combination, an extension or otherwise (iii) the structure of the initial business combination, (iv) the nature and amount of any “PIPE” or other equity issuances in connection with the initial business combination (or otherwise issued not in connection with the initial business combination but issued within the same taxable year of a redemption treated as a repurchase of stock) and (v) the content of regulations and other guidance from the U.S. Department of the Treasury. As noted above, the Excise Tax would be payable by the Company, and not by the redeeming holder, and the mechanics of any required payment of the Excise Tax have not yet been determined. The imposition of the Excise Tax could cause a reduction in the cash available on hand to complete an initial business combination or for effecting redemptions and may affect the Company’s ability to complete an initial business combination.

To mitigate the current uncertainty surrounding the implementation of the IR Act, in the event that any excise tax is accrued in connection with any redemption event, the Sponsor intends to indemnify the Company for any Excise Tax liabilities resulting from the implementation of the IR Act with respect to any future redemptions. For the avoidance of doubt, the proceeds deposited in the trust

15

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

account and the interest earned thereon shall not be used to pay for any Excise Tax due under the IR Act in connection with any redemptions of the public shares in connection with any redemption event.

On May 22, 2023, the Company’s stockholders redeemed 11,078,000 shares of common stock for a total of $113,296,457. The Company evaluated the classification and accounting of the share/ stock redemption under ASC 450, “Contingencies”. ASC 450 states that when a loss contingency exists the likelihood that the future event(s) will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing a Business Combination as of June 30, 2023 and determined that no excise tax needs to be recorded at this time.

Business Combination

On April 14, 2023, Graf entered into a Merger Agreement (the “Merger Agreement”), with Merger Sub and NKGen, pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into NKGen, with NKGen surviving the Merger in accordance with the Delaware General Corporation Law as a wholly owned subsidiary of Graf. Immediately prior to the Closing, Graf will change its name to “NKGen Biotech, Inc.” and NKGen will change its name to “NKGen Operating Biotech, Inc.” The Company’s board of directors has unanimously approved and declared advisable the Merger Agreement and the Business Combination and resolved to recommend approval of the Merger Agreement and related matters by Graf’s stockholders.

Pursuant to the Merger Agreement, the Company has agreed to issue to the equityholders of NKGen aggregate consideration of a number of shares of newly issued common stock in an amount calculated using the exchange ratio described in the Merger Agreement. At the effective time of the merger, each outstanding and unexercised NKGen option will be cancelled and converted into an option to acquire common stock.

The Merger Agreement contains customary representations, warranties and covenants by the parties thereto and the closing is subject to certain conditions as further described in the Merger Agreement. Related ancillary documents, each of which is in connection with the Closing and pursuant to the Merger, include the following: (i) a sponsor support and lockup agreement (the “Sponsor Support and Lockup Agreement”), pursuant to which the Sponsor agreed (x) to vote in favor of the merger and (y) to subject certain founder shares to a prescribed scheme; (ii) a support agreement (the “NKGen Support Agreement”), whereby NKGen stockholders agreed to vote in favor of the merger, (iii) a backstop agreement (the “Backstop Agreement”), whereby a majority stockholder of NKGen agreed to purchase a certain amount of common stock; (iv) lockup agreements (the “Lockup Agreements”), pursuant to which certain NKGen stockholders agreed to lockup their shares for a designated time period; and (v) an amended and restated registration rights agreement (the “A&R Registration Rights Agreement”) under which the company emerging from the merger agreed to register for resale.

Note 6—Common Stock Subject to Possible Redemption

The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 400,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share. On May 22, 2023, the holders of 11,078,000 shares of common stock properly exercised their right to redeem their shares. As of June 30, 2023, and December 31, 2022, there were 10,373,875 and 21,451,875 shares of common stock outstanding, of which 6,083,500 and 17,161,500 shares were subject to possible redemption and classified outside of permanent equity in the condensed consolidated balance sheets, respectively.

16

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

The common stock subject to possible redemption reflected on the condensed consolidated balance sheets is reconciled on the following table:

Common stock subject to possible redemption as of December 31, 2021

    

$

171,615,000

Plus:

 

Waiver of offering costs allocated to common stock subject to possible redemption

3,724,646

Less:

 

Adjustment for accretion of common stock subject to possible redemption amount

 

(2,175,524)

Common stock subject to possible redemption as of December 31, 2022

173,164,122

Plus:

Waiver of offering costs allocated to common stock subject to possible redemption

 

12,467

Adjustment for accretion of common stock subject to possible redemption amount

1,507,323

Common stock subject to possible redemption as of March 31, 2023

174,683,912

Plus:

Adjustment for accretion of common stock subject to possible redemption amount

1,408,829

Less:

Redemptions

(113,296,457)

Common stock subject to possible redemption as of June 30, 2023

$

62,796,284

Note 7—Stockholders’ Deficit

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding.

Common Stock — The Company is authorized to issue 400,000,000 shares of common stock, par value $0.0001. Holders of the Company’s common stock are entitled to one vote for each share. As of June 30, 2023, and December 31, 2022, there were 4,290,375 shares of common stock issued and outstanding, excluding 6,083,500 and 17,161,500 shares of common stock subject to possible redemption, respectively (see Note 6).

17

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

Note 8—Warrants

As of June 30, 2023, and December 31, 2022, the Company has 3,432,300 and 4,721,533 Public Warrants and Private Placement Warrants, respectively, outstanding.

Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable commencing 30 days after the completion of a Business Combination; provided that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use commercially reasonable efforts to file with the SEC a registration statement covering the shares of common stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of common stock issuable upon exercise of the warrants is not effective by the 60 business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

The warrant has an exercise price of $11.50 per full share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the board of directors, and in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day after the day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

Once the warrants become exercisable, the Company may redeem the outstanding warrants:

in whole and not in part;
at a price of $0.01 per warrant;
upon a minimum of 30 days’ prior written notice of redemption; and
if, and only if, the last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If the Company calls the warrants for redemption as described above, it will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.”

18

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that none of the Private Placement Warrants will be redeemable by the Company so long as they are held by the initial purchasers or any of their permitted transferees.

If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Note 9—Fair Value of Measurements

At June 30, 2023, assets held in the Trust Account were comprised of $63,529,895 in cash and $0 in U.S. Treasury securities or money market funds. Through June 30, 2023, the Company withdrew $113,296,457 for redemptions and $381,239 for franchise and income taxes from the Trust Account.

At December 31, 2022, assets held in the Trust Account totaled $ , which was comprised of $172,885,459 in U.S. Treasury securities and $602,742 in cash and money market funds. Through December 31, 2022, the Company withdrew $568,642 for franchise and income taxes from the Trust Account.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023, and December 31, 2022, and indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value:

    

Quoted Prices in

    

Significant Other

Significant Other

June 30, 2023

Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

    

(Level 3)

Liabilities

Derivative Warrant liability- Private warrants

 

$

 

$

 

$

944,310

    

Quoted Prices in

    

Significant Other

Significant Other

December 31, 2022

Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

    

(Level 3)

Assets - Investments held in Trust Account (1)

 

  

 

  

  

U.S. Treasury securities

$

172,885,459

$

$

Money market funds (1)

$

602,742

$

$

Liabilities

Derivative Warrant liability- Private warrants

$

$

$

424,940

(1)Includes cash balance held within the Trust Account of $1,264 at December 31, 2022.

Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. There were no transfers to/from Levels 1, 2, and 3 during the three and six months ended June 30, 2023 and 2022.

Level 1 assets include investments in U.S. government securities. The Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.

19

Table of Contents

GRAF ACQUISITION CORP. IV

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

The fair value of the Private Placement Warrants was measured at fair value using a Black-Scholes model. The estimated fair value of the Private Placement Warrants is determined using Level 3 inputs. Inherent in a Black-Scholes model is assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s common stock that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

For the three and six months ended June 30, 2023, the Company recognized a loss in the unaudited condensed consolidated statements of operations resulting from a increase in fair value of the derivative warrant liability of approximately $1.8 million and $2.0 million, respectively, presented as change in fair value of derivative warrant liability in the accompanying unaudited condensed consolidated statements of operations. For the three and six months ended June 30, 2022, the Company recognized a gain in the unaudited condensed consolidated statements of operations resulting from a decrease in fair value of the derivative warrant liability of approximately $1.6 million and $4.3 million, respectively, presented as change in fair value of derivative warrant liability in the accompanying unaudited condensed consolidated statements of operations.

The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement dates:

    

June 30, 2023

    

December 31, 2022

Exercise price

$

11.50

$

11.50

Share price

$

10.33

$

9.95

Expected term (years)

5.17

5.40

Volatility

0.5

%

5.50

%

Risk-free rate

4.12

%

3.98

%

Probability of completion of Business Combination

50.00

%

10.00

%

Dividend yield (per share)

0.00

%

0.00

%

The change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs, for the three and six months ended June 30, 2023, is summarized below.

Derivative warrant liability at December 31, 2022

    

$

424,940

Change in fair value of derivative warrant liability

 

236,070

Derivative warrant liability at March 31, 2023

$

661,010

Change in fair value of derivative warrant liability

283,300

Derivative warrant liability at June 30, 2023

$

944,310

The change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs, for the three and six months ended June 30, 2022, is summarized below.

Derivative warrant liability at December 31, 2021

    

$

5,571,410

Change in fair value of derivative warrant liability

(2,691,270)

Derivative warrant liability at March 31, 2022

2,880,140

Change in fair value of derivative warrant liability

(1,605,330)

Derivative warrant liability at June 30, 2022

$

1,274,810

Note 10—Subsequent Events

The Company evaluated subsequent events and transactions that occurred up to the date of these unaudited condensed consolidated financial statements were issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements.

20

Item 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References to the “Company,” “our,” “us” or “we” refer to Graf Acquisition Corp. IV. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Form 10-Q. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

Overview

We are a blank check company incorporated on January 28, 2021 as a Delaware corporation and formed for the purpose of effecting a business combination. We are an emerging growth company and, as such, we are subject to all of the risks associated with emerging growth companies.

Our sponsor is Graf Acquisition Partners IV LLC. On May 25, 2021, we consummated our IPO of 15,000,000 units, at $10.00 per unit, generating gross proceeds of $150.0 million, and incurring offering costs of approximately $8.8 million, of which approximately $5.3 million was for deferred underwriting commissions. On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased the 2,161,500 additional units, generating gross proceeds of approximately $21.6 million. We incurred additional offering costs of approximately $1.2 million in connection with the over-allotment (of which approximately $0.8 million was for deferred underwriting fees).

Simultaneously with the closing of the IPO, we consummated the private placement of 4,433,333 private placement warrants at a price of $1.50 per private placement warrant to our sponsor, generating proceeds of approximately $6.7 million. We consummated the second closing of the private placement on June 2, 2021, simultaneously with the closing of the over-allotment, resulting in the sale of an additional 288,200 private placement warrants, generating additional gross proceeds of approximately $432,000.

Upon the closing of the IPO, the over-allotment, and the private placement, $171.6 million ($10.00 per unit) of the net proceeds of the sale of the units in the IPO and of the private placement warrants in the private placement were placed in the trust account maintained by Continental Stock Transfer & Trust Company, as trustee, and will be invested only in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a business combination and (ii) the distribution of the trust account as described below. We may instruct Continental Stock Transfer & Trust Company, the trustee with respect to the trust account, to liquidate the U.S. government securities or money market funds held in the trust account and, thereafter, to hold all funds in the trust account in a bank deposit account until the earlier of the consummation of our initial business combination or our liquidation.

Our management has broad discretion with respect to the specific application of the net proceeds of the IPO, the over-allotment, and the sale of the private placement warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a business combination.

21

On May 22, 2023, the Company held a special meeting of stockholders (the “May 2023 Special Meeting”), pursuant to which the Company’s stockholders approved a proposal to amend the Charter (the “Charter Amendment”) to (i) provide the Company with the right to extend the date by which the Company must consummate its initial business combination, from May 25, 2023 to September 29, 2023, and to (ii) permit the Company’s board of directors, in its sole discretion, to elect to wind up the Company’s operations on an earlier date than the Extended Date as determined by the board of directors and included in a public announcement. In addition, on May 22, 2023, the Company filed the Charter Amendment with the Secretary of State of the State of Delaware. At the May 2023 Special Meeting, the holders of 11,078,000 shares of common stock properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.227 per share, for an aggregate redemption amount of approximately $113.3 million.

If we have not consummated an initial business combination by September 29, 2023 or any extended period of time that we may have to consummate an initial business combination as a result of an amendment to our amended and restated certificate of incorporation, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest (which interest shall be net of taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

Liquidity and Going Concern

As of June 30, 2023, we had approximately $42,000 in our operating bank account and working capital deficit of approximately $6.2 million.

Our liquidity needs through June 30, 2023 were satisfied through a payment of $25,000 from our sponsor to purchase the founder shares, the loan of approximately $67,000 from the sponsor under a promissory note, and the proceeds from the consummation of the private placement not held in the trust account. We repaid the promissory note in full on May 26, 2021. In addition, in order to finance transaction costs in connection with a business combination, the sponsor or an affiliate of the sponsor, or certain of our officers and directors may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem necessary in their sole discretion (the “working capital loans”). As of June 30, 2023, and December 31, 2022, there were $416,710 and $0 amounts outstanding under any working capital loans borrowed under the Convertible Promissory Note.

In connection with the Company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the liquidity condition, the mandatory liquidation and subsequent dissolution that will be required if the Company does not complete a business combination before September 29, 2023 (unless extended in accordance with our amended and restated certificate of incorporation) raises substantial doubt about the Company’s ability to continue as a going concern. Although Management expects that it will be able to raise additional capital to support its planned activities and complete a business combination on or prior to September 29, 2023 (unless extended in accordance with our amended and restated certificate of incorporation), it is uncertain whether it will be able to do so. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after September 29, 2023 (unless extended in accordance with our amended and restated certificate of incorporation). The unaudited condensed consolidated financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these unaudited condensed consolidated financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.

Results of Operations

Our entire activity from January 28, 2021 (inception) through June 30, 2023, was in preparation for our IPO, and since our IPO, our activity has been limited to the search for a prospective initial business combination. We will not generate any operating revenues until the closing and completion of our initial business combination. We will generate non-operating income in the form of

22

investment income from our investments held in the trust account. We expect to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended June 30, 2023, we had net loss of approximately $1.8 million which consisted approximately $2.6 million in general and administrative expenses, approximately $283,000 million in non-operating loss from the change in fair value of warrant liability, approximately $287,000 of income tax expense, approximately $50,000 of franchise tax expenses and approximately $45,000 in related party administrative expenses , offset by approximately $1.4 million in income from investments held in Trust Account.

For the three months ended June 30, 2022, we had net income of approximately $956,000, which consisted of approximately $1.6 million in non-operating gain from the change in fair value of warrant liability, approximately $125,000 in income from investments held in Trust Account, approximately $180,000 in gain on settlement of deferred underwriting commissions, and an income tax benefit of $15,000, offset by approximately $875,000 in general and administrative expenses, approximately $49,000 of franchise tax expenses, and related party administrative expenses of approximately $45,000.

For the six months ended June 30, 2023, we had a net loss of approximately $1.5 million which consisted approximately $3.4 million in general and administrative expenses, approximately $519,000 in non-operating loss from the change in fair value of warrant liability, approximately $691,000 of income tax expense, approximately $100,000 of franchise tax expenses and approximately $90,000 in related party administrative expenses , offset by approximately $3.4 million in income from investments held in Trust Account.

For the six months ended June 30, 2022, we had net income of approximately $3.0 million which consisted of approximately $4.3 million in non-operating gain from the change in fair value of warrant liability, approximately $169,000 in income from investments held in Trust Account, approximately $180,000 in gain on settlement of deferred underwriting commissions, and an income tax benefit of $15,000, offset by approximately $1.5 million in general and administrative expenses, approximately $98,000 of franchise tax expenses, and related party administrative expenses of approximately $90,000.

Contractual Obligations

We do not have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations or long-term liabilities at June 30, 2023.

Registration and Stockholder Rights

The holders of our founder shares, private placement warrants and warrants that may be issued upon conversion of working capital loans (and any shares of common stock issuable upon the exercise of the private placement warrants and warrants that may be issued upon conversion of working capital loans) were entitled to registration rights pursuant to a registration rights agreement signed upon the effective date of the IPO. These holders are entitled to make up to three demands, excluding short form registration demands, that the Company registered such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. We will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

We granted the underwriters a 45-day option from the date of the final prospectus relating to the IPO to purchase up to 2,250,000 additional units less the underwriting discounts and commissions. On June 2, 2021, the underwriters partially exercised the over-allotment option.

The underwriters were entitled to an underwriting discount of $0.20 per unit, or $3.4 million in the aggregate, paid upon the closing of the IPO ($3.0 million) and Over-Allotment (approximately $0.4 million). In addition, $0.35 per unit, or approximately $6.0 million in the aggregate was payable to the underwriters for deferred underwriting commissions (approximately $5.25 million related to the IPO and $0.8 million related to the Over-Allotment). The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. On May 16, 2022, J.P. Morgan Securities LLC (“JPM”), one of the representatives of the underwriters of the Company’s Initial Public Offering, waived their deferred underwriting fee that accrued from JPM’s participation in the Initial Public Offering of approximately $3.9 million. The Company derecognized approximately $3.7 million of the commissions waiver allocated

23

to Public Shares to the carrying value of the common stock subject to possible redemption and the remaining balance of approximately $180,000 as a gain from extinguishment of deferred underwriting commissions allocated to derivative warrant liability.

Administrative Services Agreement

On May 20, 2021, the Company entered into an agreement that provided that, commencing on the date that the Company’s securities were first listed on the NYSE through the earlier of consummation of the initial Business Combination and the liquidation, the Company agreed to pay G-SPAC Management LLC, an affiliate of the Sponsor, $15,000 per month for office space, utilities, secretarial, administrative and support services provided to the Company and members of the management team. For the three and six months ended June 30, 2023 and 2022, the Company incurred expenses of approximately $45,000 and $90,000 under this agreement, respectively. For the three and six months ended June 30, 2023 and 2022, the Company incurred expenses of approximately $45,000 and $90,000 under this agreement, respectively. As of June 30, 2023 and December 31, 2022, there were no expenses outstanding related to these expenses on the unaudited condensed consolidated balance sheets.

Chief Financial Officer Compensation

On December 21, 2022, we held a special meeting of stockholders (the “December Special Meeting”), pursuant to which our stockholders approved the payment by the Company, directly or indirectly, of $16,667.00 per month base cash compensation to the Company’s full-time Chief Financial Officer, Mr. Cross, who is not a member of our Sponsor, plus any related taxes (including, without limitation, Medicare and social security), governmental payments and health care benefits, for services rendered to the Company as an employee, contractor or otherwise from May 6, 2022 (retroactive) through the Company’s closing of a initial business combination.

Health Care Benefits

At the December Special Meeting, our stockholders also approved the payment by the Company, directly or indirectly, of up to $6,000.00 per month in aggregate for health care benefits to be provided to three of the Company’s full-time executive officers, Mr. Graf, the Chief Executive Officer, Mr. Kuznik, the Executive Vice President, General Counsel and Secretary and Ms. McKee, the Executive Vice President, Strategy, who are not otherwise receiving compensation from the Company, from December 21, 2022 through the Company’s closing of a business combination.

Convertible Promissory Note

In connection with the Extension and advances the Sponsor may make in the future to the Company for working capital expenses, on May 15, 2023, the Company issued a convertible promissory note to the Sponsor with a principal amount up to $1,500,000 (the “Convertible Promissory Note"). The Convertible Promissory Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Company’s initial business combination, or (b) the date of the Company’s liquidation. If the Company does not consummate an initial business combination by the Extended Date, the Convertible Promissory Note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. Upon maturity, the outstanding principal of the Note may be converted into warrants, at a price of $1.50 per warrant, at the option of the Sponsor. Such warrants will have terms identical to the warrants issued to the Sponsor in a private placement that closed simultaneously with the Company’s initial public offering. Any drawdowns in connection with the Convertible Promissory Note are subject to unanimous written consent of the Company's board of directors and the consent of the Sponsor. As of June 30, 2023, there was $416,710 borrowed under the Convertible Promissory Note.

The foregoing description of the Convertible Promissory Note does not purport to be complete and is qualified in its entirety by reference to the complete text of the Convertible Promissory Note, which is filed hereto as Exhibit 10.6.

Critical Accounting Policies and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets

24

and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Derivative Warrant Liability

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company will evaluate its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

The private placement warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the carrying value of the instruments to fair value at each reporting period until they are exercised. The fair value of the private placement warrants as of June 30, 2023 and December 31, 2022 is determined using Black-Scholes option pricing model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of IPO (including exercise of the over-allotment option), 17,161,500 shares of common stock subject to possible redemption at the redemption amount were presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheets.

We recognize changes in redemption value immediately as they occur and adjust the carrying value of the common stock shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Effective with the closing of the IPO (including exercise of the over-allotment option), the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

Net (Loss) Income Per Share of Common Stock

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net (loss) income per common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.

The calculation of diluted net (loss) income per common stock does not consider the effect of the warrants issued in connection with the IPO (including exercise of the over-allotment option) and the private placement to purchase an aggregate of 8,153,833 shares of common stock in the calculation of diluted (loss) income per share, because their exercise is contingent upon future events. As a result, diluted net (loss) income per share is the same as basic net (loss) income per share for the three and six months ended June 30, 2023 and 2022. Accretion associated with the redeemable common stock is excluded from earnings per share as the redemption value approximates fair value.

Recent Accounting Standards

In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods

25

within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the unaudited condensed consolidated financial statements.

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on our unaudited condensed consolidated financial statements.

Off-Balance Sheet Arrangements

As of June 30, 2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

JOBS Act

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our IPO or until we are no longer an “emerging growth company,” whichever is earlier.

Recent Developments

Item 3.  Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4.  Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended June 30, 2023, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer has concluded that during the period covered by this report, our disclosure controls and procedures were not effective as of June 30, 2023, because of a material weakness in our internal control over financial reporting identified and disclosed in our Form 10-K. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, the Company’s management has concluded that our control around the interpretation and accounting for extinguishment of a significant contingent obligation was not effectively designed or maintained. In light of this material weakness, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with GAAP. Accordingly, management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial statements.

26

Management has implemented remediation steps to improve our disclosure controls and procedures and our internal control over financial reporting. Specifically, we intend to expand and improve our review process for complex securities and related accounting standards. We have improved this process by enhancing access to accounting literature, identification of third-party professionals with whom to consult regarding complex accounting applications and consideration of additional staff with the requisite experience and training to supplement existing accounting professionals.

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, other than as described above, that occurred during the fiscal quarter ended June 30, 2023 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.  Legal Proceedings

There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such.

Item 1A. Risk Factors

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Form 10-K filed with the SEC on March 31, 2023. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

None.

27

Item 6.  Exhibits

The following exhibits are filed as part of this Quarterly Report on Form 10-Q.

Exhibit
Number

    

Description

3.1

Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2023).

3.2

Amendment to the Amended and Restated Certificate of Incorporation of Graf Acquisition Corp. IV (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 22, 2023).

10.1

Convertible Promissory Note, dated May 15, 2023, between Graf Acquisition Corp. IV and Graf Acquisition Partners, IV, LLC (incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (filed with the SEC on May 15, 2023)).

31.1

Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer Pursuant to Rule 13(a)-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

†  Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

28

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 14th day of August, 2023.

GRAF ACQUISITION CORP. IV

By:

/s/ James A. Graf

Name:

James A. Graf

Title:

Chief Executive Officer (Principal Executive Officer)

By:

/s/ Sabrina McKee

Name:

Sabrina McKee

Title:

Chief Financial Officer (Principal Financial and Accounting Officer)

29

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, James A. Graf, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2023 of Graf Acquisition Corp. IV;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the unaudited condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: August 14, 2023

By:

/s/ James A. Graf

James A. Graf

Chief Executive Officer

(Principal Executive Officer)


EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sabrina McKee, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2023 of Graf Acquisition Corp. IV

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the unaudited condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: August 14, 2023

By:

/s/ Sabrina McKee

Sabrina McKee

Chief Financial Officer and Treasurer

(Principal Financial Officer)


EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Graf Acquisition Corp. IV (the “Company”) on Form 10-Q for the three months ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James. A Graf, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2023

/s/ James A. Graf

Name:

James A. Graf

Title:

Chief Executive Officer

(Principal Executive Officer)


EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Graf Acquisition Corp. IV (the “Company”) on Form 10-Q for the three months ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sabrina McKee, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2023

/s/ Sabrina McKee

Name:

Sabrina McKee

Title:

Chief Financial Officer and Treasurer

(Principal Financial Officer)


v3.23.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 14, 2023
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2023  
Entity File Number 001-40427  
Entity Registrant Name GRAF ACQUISITION CORP. IV  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 86-2191918  
Entity Address, Address Line One 1790 Hughes Landing Blvd., Suite 400  
Entity Address, City or Town The Woodlands  
Entity Address State Or Province TX  
Entity Address, Postal Zip Code 77380  
City Area Code 346  
Local Phone Number 442-0819  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Entity Common Stock, Shares Outstanding   10,373,875
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Central Index Key 0001845459  
Amendment Flag false  
Transition Report true  
Common Stock, par value $0.0001 per share    
Document and Entity Information    
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol GFOR  
Security Exchange Name NYSE  
Units, each consisting of one share of common stock and one-fifth of one redeemable warrant    
Document and Entity Information    
Title of 12(b) Security Units, each consisting of one share of common stock and one-fifth of one redeemable warrant  
Trading Symbol GFOR.U  
Security Exchange Name NYSE  
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share    
Document and Entity Information    
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share  
Trading Symbol GFOR WS  
Security Exchange Name NYSE  
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 41,459 $ 635,155
Prepaid expenses 34,179 242,752
Total current assets 75,638 877,907
Cash and investments held in Trust Account 63,529,895 173,488,201
Total Assets 63,605,533 174,366,108
Current liabilities:    
Accounts payable 163,344 177,157
Franchise tax payable 66,255 42,705
Accrued expenses 5,050,540 2,444,352
Due to related party 32,809 0
Income tax payable 572,146 181,374
Convertible promissory note - related party 416,710 0
Total current liabilities 6,301,804 2,845,588
Derivative warrant liability 944,310 424,940
Deferred underwriting commissions in connection with the initial public offering 2,102,284 2,102,284
Total Liabilities 9,348,398 5,372,812
Commitments and Contingencies
Stockholders' Deficit:    
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding as of June 30, 2023 and December 31, 2022
Accumulated deficit (8,539,578) (4,171,255)
Total stockholders' deficit (8,539,149) (4,170,826)
Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders' Deficit 63,605,533 174,366,108
Common stock subject to possible redemption    
Current liabilities:    
Common stock subject to possible redemption; 6,083,500 and 17,161,500 shares at redemption value of approximately $10.32 and $10.09 per share as of June 30, 2023 and December 31, 2022, respectively 62,796,284 173,164,122
Common stock not subject to possible redemption    
Stockholders' Deficit:    
Common stock, $0.0001 par value; 400,000,000 shares authorized; 4,290,375 shares issued and outstanding (excluding 6,083,500 and 17,161,500 shares subject to possible redemption) as of June 30, 2023 and December 31, 2022, respectively $ 429 $ 429
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Common stock shares subject to possible redemption 6,083,500  
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 400,000,000 400,000,000
Common stock subject to possible redemption    
Common stock shares subject to possible redemption 6,083,500 17,161,500
Common stock subject to possible redemption, approximate redemption value (in dollars per share) $ 10.32 $ 10.09
Common stock not subject to possible redemption    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 400,000,000 400,000,000
Common stock, shares issued 4,290,375 4,290,375
Common stock, shares outstanding 4,290,375 4,290,375
v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        
General and administrative expenses $ 2,581,577 $ 874,637 $ 3,441,419 $ 1,512,778
General and administrative expenses - related party 45,000 45,000 90,000 90,000
Franchise tax expenses 50,000 49,315 100,000 98,082
Loss from operations (2,676,577) (968,952) (3,631,419) (1,700,860)
Other income (expense)        
Change in fair value of derivative warrant liability (283,300) 1,605,330 (519,370) 4,296,600
Gain on settlement of deferred underwriting commissions   179,595   179,595
Income from investments held in Trust Account 1,415,607 124,764 3,389,390 168,792
Other income (expense) 1,132,307 1,909,689 2,870,020 4,644,987
Net (loss) income before income tax (1,544,270) 940,737 (761,399) 2,944,127
Income tax (expense) benefit (286,778) 15,402 (690,772) 15,402
Net (loss) income $ (1,831,048) $ 956,139 $ (1,452,171) $ 2,959,529
Weighted average shares outstanding of common stock, basic 16,825,897 21,451,875 19,126,107 21,451,875
Weighted average shares outstanding of common stock, diluted 16,825,897 21,451,875 19,126,107 21,451,875
Basic net (loss) income per share, common stock $ (0.11) $ 0.04 $ (0.08) $ 0.14
Diluted net (loss) income per share, common stock $ (0.11) $ 0.04 $ (0.08) $ 0.14
v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
Common Stock
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2021 $ 429 $ (10,895,130) $ (10,894,701)
Balance at the beginning (in shares) at Dec. 31, 2021 4,290,375    
Increase (decrease) in Stockholders' Deficit      
Net income (loss)   2,003,390 2,003,390
Balance at the end at Mar. 31, 2022 $ 429 (8,891,740) (8,891,311)
Balance at the end (in shares) at Mar. 31, 2022 4,290,375    
Balance at the beginning at Dec. 31, 2021 $ 429 (10,895,130) (10,894,701)
Balance at the beginning (in shares) at Dec. 31, 2021 4,290,375    
Increase (decrease) in Stockholders' Deficit      
Net income (loss)     2,959,529
Balance at the end at Jun. 30, 2022 $ 429 (4,210,955) (4,210,526)
Balance at the end (in shares) at Jun. 30, 2022 4,290,375    
Balance at the beginning at Dec. 31, 2021 $ 429 (10,895,130) (10,894,701)
Balance at the beginning (in shares) at Dec. 31, 2021 4,290,375    
Balance at the end at Dec. 31, 2022 $ 429 (4,171,255) (4,170,826)
Balance at the end (in shares) at Dec. 31, 2022 4,290,375    
Balance at the beginning at Mar. 31, 2022 $ 429 (8,891,740) (8,891,311)
Balance at the beginning (in shares) at Mar. 31, 2022 4,290,375    
Increase (decrease) in Stockholders' Deficit      
Net income (loss)   956,139 956,139
Adjustment for accretion of common stock subject to possible redemption amount   3,724,646 3,724,646
Balance at the end at Jun. 30, 2022 $ 429 (4,210,955) (4,210,526)
Balance at the end (in shares) at Jun. 30, 2022 4,290,375    
Balance at the beginning at Dec. 31, 2022 $ 429 (4,171,255) (4,170,826)
Balance at the beginning (in shares) at Dec. 31, 2022 4,290,375    
Increase (decrease) in Stockholders' Deficit      
Net income (loss)   378,877 378,877
Adjustment for accretion of common stock subject to possible redemption amount   (1,507,323) (1,507,323)
Balance at the end at Mar. 31, 2023 $ 429 (5,299,701) (5,299,272)
Balance at the end (in shares) at Mar. 31, 2023 4,290,375    
Balance at the beginning at Dec. 31, 2022 $ 429 (4,171,255) (4,170,826)
Balance at the beginning (in shares) at Dec. 31, 2022 4,290,375    
Increase (decrease) in Stockholders' Deficit      
Net income (loss)     (1,452,171)
Balance at the end at Jun. 30, 2023 $ 429 (8,539,578) (8,539,149)
Balance at the end (in shares) at Jun. 30, 2023 4,290,375    
Balance at the beginning at Mar. 31, 2023 $ 429 (5,299,701) (5,299,272)
Balance at the beginning (in shares) at Mar. 31, 2023 4,290,375    
Increase (decrease) in Stockholders' Deficit      
Net income (loss)   (1,831,048) (1,831,048)
Adjustment for accretion of common stock subject to possible redemption amount   (1,408,829) (1,408,829)
Balance at the end at Jun. 30, 2023 $ 429 $ (8,539,578) $ (8,539,149)
Balance at the end (in shares) at Jun. 30, 2023 4,290,375    
v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Cash Flows from Operating Activities:      
Net (loss) income   $ (1,452,171) $ 2,959,529
Adjustments to reconcile net (loss) income to net cash used in operating activities:      
Change in fair value of derivative warrant liability $ (1,605,330) 519,370 (4,296,600)
Gain on settlement of deferred underwriting commissions (179,595)   (179,595)
Income from investments held in Trust Account   (3,389,390) (168,792)
Change in operating assets and liabilities:      
Prepaid expenses   208,573 288,199
Prepaid expenses - related party     (13,173)
Accounts payable   (13,813) 79,438
Franchise tax payable   23,550 (56,214)
Income tax payable   390,772 (15,402)
Due to related party   32,809  
Accrued expenses   2,618,655 940,161
Net cash used in operating activities   (1,061,645) (462,449)
Cash Flows from Investing Activities:      
Investment of cash into Trust Account   (330,000)  
Cash withdrawals from Trust Account to pay for taxes   381,239  
Cash withdrawn from Trust Account in connection with redemption   113,296,457  
Net cash provided by investing activities   113,347,696  
Cash Flows from Financing Activities:      
Proceeds from convertible promissory note - related party   416,710  
Redemption of common stock   (113,296,457)  
Net cash used in financing activities   (112,879,747)  
Net change in cash   (593,696) (462,449)
Cash - beginning of the period   635,155 1,722,506
Cash - end of the period $ 1,260,057 41,459 $ 1,260,057
Supplementary cash flow information:      
Cash paid for income taxes   300,000  
Supplemental disclosure of noncash activities:      
Extinguishment of accrued expenses related to offering costs   $ (13,924)  
v3.23.2
Description of Organization and Business Operations
6 Months Ended
Jun. 30, 2023
Description of Organization and Business Operations  
Description of Organization and Business Operations

Note 1—Description of Organization and Business Operations

Graf Acquisition Corp. IV (“Graf”) is a newly organized blank check company incorporated in Delaware and formed for the purpose of effecting into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.

On December 9, 2021, Graf incorporated Austria Merger Sub, Inc. (“Merger Sub”), a Delaware corporation. Graf and its subsidiary are collectively referred to as the “Company.”

On April 14, 2023, Graf entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merger Sub and NKGen Biotech, Inc., a Delaware corporation (“NKGen”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into NKGen (the “Merger”), with NKGen surviving the Merger in accordance with the Delaware General Corporation Law as a wholly owned subsidiary of Graf (the Merger, together with the other transactions contemplated by the Merger Agreement and the related ancillary agreements, the “Business Combination”).

As of June 30, 2023, the Company had not yet commenced operations. All activity for the period from January 28, 2021 (inception) through June 30, 2023, relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on the proceeds derived from the Initial Public Offering.

The Company’s sponsor is Graf Acquisition Partners IV LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on May 20, 2021. On May 25, 2021, the Company consummated its Initial Public Offering of 15,000,000 units (the “Units” and, with respect to the common stock included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $150.0 million, and incurring offering costs of approximately $8.8 million, of which approximately $5.3 million was for deferred underwriting commissions (see Note 5). The Company granted the underwriter a 45-day option to purchase up to an additional 2,250,000 Units at the Initial Public Offering price to cover over-allotments. On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased 2,161,500 additional Units (the “Additional Units”), generating gross proceeds of approximately $21.6 million (the “Over-Allotment”). The Company incurred additional offering costs of approximately $1.2 million in connection with the Over-Allotment (of which approximately $757,000 was for deferred underwriting fees).

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 4,433,333 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $6.7 million (see Note 4). Simultaneously with the closing of the Over-Allotment on June 2, 2021, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 288,200 Private Placement Warrants at $1.50 per Private Placement Warrant (the “Additional Private Placement Warrants”), generating additional gross proceeds of approximately $432,000.

Upon the closing of the Initial Public Offering, Over-Allotment, and Private Placement, $171.6 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering, Over-Allotment and of the Private Placement Warrants in the Private Placement were placed in a trust account (“Trust Account”) in the United States maintained by Continental Stock Transfer & Trust Company, as trustee, and has been invested only in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, or the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide the holders of Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially at $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). These Public Shares were recorded at a redemption value and classified as temporary equity, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Charter”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Founder Shares (as defined in Note 4) prior to this Initial Public Offering (the “Initial Stockholders”) agreed to vote their Founder Shares and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Stockholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. In addition, the Company agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor.

Notwithstanding the foregoing, the Charter provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the shares of common stock sold in the Initial Public Offering, without the prior consent of the Company.

The Company’s Sponsor, executive officers, and directors have agreed not to propose an amendment to the Charter that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their shares of common stock in conjunction with any such amendment.

If a Business Combination has not been consummated by September 29, 2023 (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

On May 22, 2023, the Company held a special meeting of stockholders (the "Meeting"), pursuant to which the Company's stockholders approved a proposal to amend the Charter (the "Charter Amendment") to (i) provide the Company with the right to extend the date by which the Company must consummate its initial business combination (the "Extension"), from May 25, 2023 to September 29, 2023 (the "Extended Date"), and to and (ii) permit the Company's board of directors, in its sole discretion, to elect to wind up the Company's operations on an earlier date than the Extended Date as determined by the board of directors and included in a public announcement. In addition, on May 22, 2023, the Company filed the Charter Amendment with the Secretary of State of the State of Delaware. In addition, in connection with the Extension, the Company shall deposit into the Trust Account $0.03 per Public Share of common stock that is not redeemed, up to $165,000, for each calendar month (or pro rata portion thereof if less than a full month), until the earlier to occur of (i) September 29, 2023, (ii) the closing of the Business Combination and (iii) the Company’s liquidation.

In connection with the vote to approve the Extension Amendment Proposal, the holders of 11,078,000 shares of common stock properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.227 per share, for an aggregate redemption amount of approximately $113.3 million.

The Initial Stockholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account.

The Company will seek to have all third parties (except the Company’s independent registered public accounting firm) and any prospective target businesses enter into valid and enforceable agreements with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account. Nevertheless, there is no guarantee that vendors, service providers and prospective target businesses will execute such agreements. The Company’s insiders agreed that they will be jointly and severally liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per Public Share, except as to any claims by a third party who executed an agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. However, the Company’s insiders may not be able to satisfy their indemnification obligations. Moreover, the Company’s insiders will not be liable to the Public Stockholders and instead will only have liability to the Company.

Liquidity and Going Concern

As of June 30, 2023, the Company had approximately $41,000 in its operating bank account and working capital deficit of approximately $6.2 million.

The Company’s liquidity needs through June 30, 2023 were satisfied through a payment of $25,000 from the Sponsor to purchase the Founder Shares (as defined in Note 4), the loan of approximately $67,000 from the Sponsor under the Note (as defined in Note 4 to the unaudited condensed consolidated financial statements), and the proceeds from the consummation of the Private Placement not held in the Trust Account. The Company repaid the Note in full on May 26, 2021. In addition, in order to finance transaction costs

in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors, may, but are not obligated to, provide Working Capital Loans (as defined in Note 4 to the unaudited condensed consolidated financial statements). As of June 30, 2023, and December 31, 2022, there were $416,710 and $0 amounts outstanding under any Working Capital Loans, respectively, borrowed under the Convertible Promissory Note (defined in Note 4).

In connection with the Company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the liquidity condition, the mandatory liquidation and subsequent dissolution that will be required if the Company does not complete a business combination before September 29, 2023 (unless extended in accordance with the amended and restated certificate of incorporation) raises substantial doubt about the Company’s ability to continue as a going concern. Although management expects that it will be able to raise additional capital to support its planned activities and complete a business combination on or prior to September 29, 2023 (unless extended in accordance with the amended and restated certificate of incorporation), it is uncertain whether it will be able to do so. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after September 29, 2023 (unless extended in accordance with the amended and restated certificate of incorporation). The unaudited condensed consolidated financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Basis of Presentation and Summary of Significant Accounting Policies  
Basis of Presentation and Summary of Significant Accounting Policies

Note 2—Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these condensed financial statements as they are not required for interim financial statements under GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the period presented. Operating results for the three and six months ended June 30, 2023, and since inception are not necessarily indicative of the results that may be expected through December 31, 2023, or any future period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2023.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of income and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2023, and December 31, 2022.

Cash and investments Held in the Trust Account

The Company’s portfolio of investments is comprised of cash and U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. Gains and losses resulting from the change in fair value of these securities are included in income on investments held in the Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB Topic ASC 820, “Fair Value Measurements,” equals or approximates the carrying amounts represented in the condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liabilities.

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Derivative Warrant Liability

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company will evaluate its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

The Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the carrying value of the instruments to fair value at each reporting period until they are exercised. The fair value of the Private Placement Warrants as of June 30, 2023, and December 31, 2022, is determined using Black-Scholes option pricing model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Offering Costs Associated with the Initial Public Offering

Offering costs consist of legal, underwriting fees, accounting, and other costs incurred through the condensed consolidated balance sheet date that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liability will be expensed as incurred, presented as non-operating expenses in the condensed statements of operations. Offering costs associated with the Public Shares issued were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as liability instruments and is measured at fair value. Conditionally redeemable common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain

redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, June 30, 2023 and December 31, 2022, 6,083,500 and 17,161,500 shares of common stock subject to possible redemption at the redemption amount were presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed consolidated balance sheets, respectively.

Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering (including exercise of the over-allotment option), the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2023 and December 31, 2022, the Company had full valuation allowance against the deferred tax assets.

ASC 740 prescribes a recognition threshold and a measurement attribute for the unaudited condensed consolidated financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2023 and December 31, 2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of June 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.

Net (Loss) Income per Share of Common Stock

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net (loss) income per common stock is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding during the period.

The calculation of diluted net (loss) income per common stock does not consider the effect of the warrants issued in connection with the Initial Public Offering (including exercise of the over-allotment option) and the Private Placement to purchase an aggregate of 8,153,833 shares of common stock in the calculation of diluted (loss) income per common stock, because their exercise is contingent upon future events. As a result, diluted net (loss) income per common stock is the same as basic net (loss) income per common stock for the three and six months ended June 30, 2023 and 2022. Accretion associated with the redeemable common stock is excluded from earnings per share as the redemption value approximates fair value.

Recent Accounting Pronouncements

In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820, “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the unaudited condensed consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.

v3.23.2
Initial Public Offering
6 Months Ended
Jun. 30, 2023
Initial Public Offering  
Initial Public Offering

Note 3—Initial Public Offering

On May 25, 2021, the Company consummated its Initial Public Offering of 15,000,000 Units, at $10.00 per Unit, generating gross proceeds of $150.0 million, and incurring offering costs of approximately $8.8 million, of which approximately $5.3 million was for deferred underwriting commissions. The Company granted the underwriters a 45-day option to purchase up to 2,250,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased 2,161,500 additional Units (the “Additional Units”), generating gross proceeds of approximately $21.6 million (the “Over-Allotment”). The Company incurred additional offering costs of approximately $1.2 million in connection with the Over-Allotment (of which approximately $0.8 million was for deferred underwriting fees). On May 16, 2022, one of the underwriters waived their deferred fee of approximately $3.9 million.

Each Unit consists of one share of common stock, and one-fifth of one redeemable warrant (“Public Warrant”). Each whole Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 7).

v3.23.2
Related Party Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions  
Related Party Transactions

Note 4—Related Party Transactions

Founder Shares

On February 13, 2021, Graf Acquisition Partners LLC (“Graf LLC”) paid an aggregate of $25,000 for certain offering costs on behalf of the Company in exchange for issuance of 4,312,500 shares of common stock (the “Founder Shares”). On April 2, 2021, Graf LLC transferred all of its Founder shares to the Sponsor. On April 8, 2021, the Sponsor transferred 20,000 Founder Shares to each of the Company’s independent directors, resulting in the Sponsor holding 4,252,500 Founder Shares. The holders of the Founder Shares agreed to forfeit up to an aggregate of 562,500 Founder Shares, on a pro rata basis, to the extent that the option to purchase additional units is not exercised in full by the underwriters, so that the Founder Shares will represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters partially exercised their over-allotment option on June 2, 2021, and forfeited the remaining option; and, as a result, an aggregate of 22,125 Founder Shares were forfeited, resulting in 4,290,375 Founder Shares outstanding. On July 14, 2021, the Sponsor transferred 20,000 Founder Shares to Alexandra Lebenthal in connection with her appointment to the Company’s board of directors.

The Initial Stockholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 120 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Private Placement

Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 4,433,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $6.7 million. Simultaneously with the closing of the Over-Allotment on June 2, 2021, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 288,200 Private Placement Warrants at $1.50 per Private Placement Warrant (the “Additional Private Placement Warrants”), generating additional gross proceeds of approximately $0.4 million.

Each whole Private Placement Warrant entitles the holder thereof to purchase one common stock at an exercise price of $11.50 per full share. A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees (see Note 8).

Related Party Loans

On January 29, 2021, the Sponsor agreed to loan the Company up to $150,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note was non-interest bearing, unsecured and due upon the consummation of the Initial Public Offering. The Company had borrowed approximately $70,000 under the Note. The Note was paid back in full on May 26, 2021. Subsequent to the repayment, the facility was no longer available to the Company.

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or any of the Company’s officers or directors may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion (the “Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the initial Business Combination, without interest. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used for such repayment. Up to $1,500,000 of such Working Capital Loans may be convertible into additional warrants at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans.

In connection with the Extension and advances the Sponsor may make in the future to the Company for working capital expenses, on May 15, 2023, the Company issued a convertible promissory note to the Sponsor with a principal amount up to $1,500,000 (the "Convertible Promissory Note"). The Convertible Promissory Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Company's initial business combination, or (b) the date of the Company's liquidation. If the Company does not consummate an initial business combination by the Extended Date, the Convertible Promissory Note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. Subject to the terms and conditions of the Merger Agreement, dated as of April 14, 2023, by and among Graf, Merger Sub and NKGen, upon maturity, the outstanding principal of the Note may be converted into warrants, at a price of $1.50 per warrant, at the option of the Sponsor. Such warrants will have terms identical to the warrants issued to the Sponsor in a private placement that closed simultaneously with the Company's initial public offering. Any drawdowns in connection with the Convertible Promissory Note are subject to unanimous written consent of the Company's board of directors and the consent of the Sponsor. In no event shall the quantity of warrants issued exceed one million (1,000,000) warrants. As of June 30, 2023, and December 31, 2022, the Company had $416,710 and $0, respectively, borrowings under the Convertible Promissory Note.

Administrative Services Agreement

On May 20, 2021, the Company entered into an agreement that provided that, commencing on the date that the Company’s securities were first listed on the NYSE through the earlier of consummation of the initial Business Combination and the liquidation, the Company agreed to pay G-SPAC Management LLC, an affiliate of the Sponsor, $15,000 per month for office space, utilities, secretarial, administrative and support services provided to the Company and members of the management team. For the three and six months ended June 30, 2023, the Company incurred expenses of approximately $45,000 and $90,000 under this agreement, respectively.

As of June 30, 2023 and December 31, 2022, there was no outstanding balance on the unaudited condensed consolidated balance sheets for these expenses.

Other Related Party Transactions

On December 21, 2022, at a special meeting of stockholders, the Company’s stockholders approved the payment of compensation of $16,667 per month base to the Company’s full-time Chief Financial Officer plus any related taxes (including, without limitation, Medicare and social security), governmental payments and health care benefits, for services rendered to the Company as an employee, contractor or otherwise from May 6, 2022 (retroactive) through the Company’s closing of a Business Combination. The stockholders also approved the payment of up to $6,000 per month in aggregate for health care benefits for the officers of the Company who are not otherwise receiving compensation from the Company. For the three and six months ended June 30, 2023, the Company incurred expenses of approximately $81,000 and $170,000 under this agreement, respectively. For the three and six months ended June 30, 2022, the Company did not incur expenses under this agreement. As of June 30, 2023 and December 31, 2022, there was an outstanding balance of $32,809 and $0 reported as due to related party for these expenses on the unaudited condensed consolidated balance sheets, respectively.

In addition, the Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, officers or directors, or their affiliates. Any such payments prior to an initial Business Combination will be made from funds held outside the Trust Account. As of June 30, 2023 and December 31, 2022, there was an outstanding balance of $6,652 and $0, respectively, reported as accrued expenses for reimbursable expenses on the unaudited condensed consolidated balance sheets.

v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies  
Commitments and Contingencies

Note 5—Commitments and Contingencies

Registration and Stockholder Rights

The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) were entitled to registration rights pursuant to a registration rights agreement signed upon the effective date of the Initial Public Offering. These holders were entitled to make up to three demands, excluding short form registration demands, that the Company registered such securities for sale under the Securities Act. In addition, these holders will have “piggyback” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 2,250,000 additional Units less the underwriting discounts and commissions. On June 2, 2021, the underwriters partially exercised the over-allotment option. On June 2, 2021, the underwriters partially exercised the over-allotment option and purchased an additional 2,161,500 Units.

The underwriters were entitled to an underwriting discount of $0.20 per unit, or $3.4 million in the aggregate, paid upon the closing of the Initial Public Offering ($3.0 million) and Over-Allotment (approximately $0.4 million). In addition, $0.35 per unit, or approximately $6.0 million in the aggregate was payable to the underwriters for deferred underwriting commissions (approximately $5.25 million related to the Initial Public Offering and $0.8 million related to the Over-Allotment). The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. On May 16, 2022, J.P. Morgan Securities LLC (“JPM”), one of the representatives of the underwriters of the Company’s Initial Public Offering, waived their deferred underwriting fee that accrued from JPM’s participation in the Initial Public Offering of approximately $3.9 million. The Company derecognized approximately $3.7 million of the commissions waiver allocated to Public Shares to the carrying value of the common stock subject to possible redemption and the remaining balance of approximately $180,000 as a gain from extinguishment of deferred underwriting commissions allocated to derivative warrant liability.

Vendor Agreement

On May 8, 2023, the Company entered into an agreement with a vendor for capital market advisement services related to the Business Combination Agreement. The agreement calls for the vendor to receive an advisory fee payable in cash or a combination of cash and common stock of the surviving entity following the Business Combination. The advisory fee payable is as follows (i) $2,000,000 in cash and $2,000,000 in common stock if the total capital raised involved in the Business Combination is less than $20,000,000 or (ii) $2,500,000 in cash and $2,000,000 in common stock if the total capital raised involved in the Business Combination is greater than or equal to $20,000,000 and less than $40,000,000 or (iii) 4,000,000 in cash and $1,000,000 in common stock if the total capital raised involved in the Business Combination is greater than or equal to $40,000,000 and less than $50,000,000 or (iv) 5,000,000 in cash if the total capital raised involved in the Business Combination is greater than or equal to $50,000,000. The Company is also required to reimburse the vendor for out-of-pocket expenses which are capped at an aggregate of $200,000, of which approximately $4,500 has been accrued as of June 30, 2023 and included in accrued expenses on the unaudited condensed balance sheets.

Risks and Uncertainties

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy is not determinable as of the date of these unaudited condensed consolidated financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed consolidated financial statements.

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (the “IR Act”), which, among other things, imposes a new 1% U.S. federal excise tax on certain repurchases of stock by “covered corporations” (which include publicly traded domestic (i.e., U.S.) corporations) beginning in 2023, with certain exceptions (the “Excise Tax”). The Excise Tax is imposed on the repurchasing corporation itself, not its stockholders from which the stock is repurchased. Because the Company is a Delaware corporation and its securities are trading on the NYSE, the Company is a “covered corporation” for this purpose. The amount of the Excise Tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the Excise Tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the Excise Tax.

On December 27, 2022, the Treasury published Notice 2023-2, which provided clarification on some aspects of the application of the Excise Tax, including with respect to some transactions in which special purpose acquisition companies typically engage. In the notice, the Treasury appears to have intended to exempt from the excise tax any distributions, including those that occur in connection with redemptions, by a corporation in the same year it completely liquidates, but the guidance is not clearly drafted and arguably could be interpreted to have a narrower application. Consequently, a substantial risk remains that any redemptions would be subject to the Excise Tax, including in circumstances where the Company either engages in a business combination in 2023 in which the Company does not issue shares sufficient to offset the earlier redemptions or liquidates later in 2023.

Because the application of the Excise Tax is not entirely clear, any redemption or other repurchase effected by the Company, in connection with a business combination, extension vote or otherwise, may be subject to the Excise Tax. Whether and to what extent the Company would be subject to the Excise Tax on a redemption of shares of common stock or other stock issued by the Company would depend on a number of factors, including (i) whether the redemption is treated as a repurchase of stock for purposes of the Excise Tax, (ii) the fair market value of the redemption treated as a repurchase of stock in connection with the initial business combination, an extension or otherwise (iii) the structure of the initial business combination, (iv) the nature and amount of any “PIPE” or other equity issuances in connection with the initial business combination (or otherwise issued not in connection with the initial business combination but issued within the same taxable year of a redemption treated as a repurchase of stock) and (v) the content of regulations and other guidance from the U.S. Department of the Treasury. As noted above, the Excise Tax would be payable by the Company, and not by the redeeming holder, and the mechanics of any required payment of the Excise Tax have not yet been determined. The imposition of the Excise Tax could cause a reduction in the cash available on hand to complete an initial business combination or for effecting redemptions and may affect the Company’s ability to complete an initial business combination.

To mitigate the current uncertainty surrounding the implementation of the IR Act, in the event that any excise tax is accrued in connection with any redemption event, the Sponsor intends to indemnify the Company for any Excise Tax liabilities resulting from the implementation of the IR Act with respect to any future redemptions. For the avoidance of doubt, the proceeds deposited in the trust

account and the interest earned thereon shall not be used to pay for any Excise Tax due under the IR Act in connection with any redemptions of the public shares in connection with any redemption event.

On May 22, 2023, the Company’s stockholders redeemed 11,078,000 shares of common stock for a total of $113,296,457. The Company evaluated the classification and accounting of the share/ stock redemption under ASC 450, “Contingencies”. ASC 450 states that when a loss contingency exists the likelihood that the future event(s) will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing a Business Combination as of June 30, 2023 and determined that no excise tax needs to be recorded at this time.

Business Combination

On April 14, 2023, Graf entered into a Merger Agreement (the “Merger Agreement”), with Merger Sub and NKGen, pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into NKGen, with NKGen surviving the Merger in accordance with the Delaware General Corporation Law as a wholly owned subsidiary of Graf. Immediately prior to the Closing, Graf will change its name to “NKGen Biotech, Inc.” and NKGen will change its name to “NKGen Operating Biotech, Inc.” The Company’s board of directors has unanimously approved and declared advisable the Merger Agreement and the Business Combination and resolved to recommend approval of the Merger Agreement and related matters by Graf’s stockholders.

Pursuant to the Merger Agreement, the Company has agreed to issue to the equityholders of NKGen aggregate consideration of a number of shares of newly issued common stock in an amount calculated using the exchange ratio described in the Merger Agreement. At the effective time of the merger, each outstanding and unexercised NKGen option will be cancelled and converted into an option to acquire common stock.

The Merger Agreement contains customary representations, warranties and covenants by the parties thereto and the closing is subject to certain conditions as further described in the Merger Agreement. Related ancillary documents, each of which is in connection with the Closing and pursuant to the Merger, include the following: (i) a sponsor support and lockup agreement (the “Sponsor Support and Lockup Agreement”), pursuant to which the Sponsor agreed (x) to vote in favor of the merger and (y) to subject certain founder shares to a prescribed scheme; (ii) a support agreement (the “NKGen Support Agreement”), whereby NKGen stockholders agreed to vote in favor of the merger, (iii) a backstop agreement (the “Backstop Agreement”), whereby a majority stockholder of NKGen agreed to purchase a certain amount of common stock; (iv) lockup agreements (the “Lockup Agreements”), pursuant to which certain NKGen stockholders agreed to lockup their shares for a designated time period; and (v) an amended and restated registration rights agreement (the “A&R Registration Rights Agreement”) under which the company emerging from the merger agreed to register for resale.

v3.23.2
Common Stock Subject to Possible Redemption
6 Months Ended
Jun. 30, 2023
Common Stock Subject to Possible Redemption  
Common Stock Subject to Possible Redemption

Note 6—Common Stock Subject to Possible Redemption

The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 400,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share. On May 22, 2023, the holders of 11,078,000 shares of common stock properly exercised their right to redeem their shares. As of June 30, 2023, and December 31, 2022, there were 10,373,875 and 21,451,875 shares of common stock outstanding, of which 6,083,500 and 17,161,500 shares were subject to possible redemption and classified outside of permanent equity in the condensed consolidated balance sheets, respectively.

The common stock subject to possible redemption reflected on the condensed consolidated balance sheets is reconciled on the following table:

Common stock subject to possible redemption as of December 31, 2021

    

$

171,615,000

Plus:

 

Waiver of offering costs allocated to common stock subject to possible redemption

3,724,646

Less:

 

Adjustment for accretion of common stock subject to possible redemption amount

 

(2,175,524)

Common stock subject to possible redemption as of December 31, 2022

173,164,122

Plus:

Waiver of offering costs allocated to common stock subject to possible redemption

 

12,467

Adjustment for accretion of common stock subject to possible redemption amount

1,507,323

Common stock subject to possible redemption as of March 31, 2023

174,683,912

Plus:

Adjustment for accretion of common stock subject to possible redemption amount

1,408,829

Less:

Redemptions

(113,296,457)

Common stock subject to possible redemption as of June 30, 2023

$

62,796,284

v3.23.2
Stockholders' Deficit
6 Months Ended
Jun. 30, 2023
Stockholders' Deficit  
Stockholders' Deficit

Note 7—Stockholders’ Deficit

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding.

Common Stock — The Company is authorized to issue 400,000,000 shares of common stock, par value $0.0001. Holders of the Company’s common stock are entitled to one vote for each share. As of June 30, 2023, and December 31, 2022, there were 4,290,375 shares of common stock issued and outstanding, excluding 6,083,500 and 17,161,500 shares of common stock subject to possible redemption, respectively (see Note 6).

v3.23.2
Warrants
6 Months Ended
Jun. 30, 2023
Warrants  
Warrants

Note 8—Warrants

As of June 30, 2023, and December 31, 2022, the Company has 3,432,300 and 4,721,533 Public Warrants and Private Placement Warrants, respectively, outstanding.

Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable commencing 30 days after the completion of a Business Combination; provided that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use commercially reasonable efforts to file with the SEC a registration statement covering the shares of common stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of common stock issuable upon exercise of the warrants is not effective by the 60 business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

The warrant has an exercise price of $11.50 per full share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the board of directors, and in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day after the day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

Once the warrants become exercisable, the Company may redeem the outstanding warrants:

in whole and not in part;
at a price of $0.01 per warrant;
upon a minimum of 30 days’ prior written notice of redemption; and
if, and only if, the last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If the Company calls the warrants for redemption as described above, it will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.”

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that none of the Private Placement Warrants will be redeemable by the Company so long as they are held by the initial purchasers or any of their permitted transferees.

If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

v3.23.2
Fair Value of Measurements
6 Months Ended
Jun. 30, 2023
Fair Value of Measurements  
Fair Value of Measurements

Note 9—Fair Value of Measurements

At June 30, 2023, assets held in the Trust Account were comprised of $63,529,895 in cash and $0 in U.S. Treasury securities or money market funds. Through June 30, 2023, the Company withdrew $113,296,457 for redemptions and $381,239 for franchise and income taxes from the Trust Account.

At December 31, 2022, assets held in the Trust Account totaled $ , which was comprised of $172,885,459 in U.S. Treasury securities and $602,742 in cash and money market funds. Through December 31, 2022, the Company withdrew $568,642 for franchise and income taxes from the Trust Account.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023, and December 31, 2022, and indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value:

    

Quoted Prices in

    

Significant Other

Significant Other

June 30, 2023

Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

    

(Level 3)

Liabilities

Derivative Warrant liability- Private warrants

 

$

 

$

 

$

944,310

    

Quoted Prices in

    

Significant Other

Significant Other

December 31, 2022

Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

    

(Level 3)

Assets - Investments held in Trust Account (1)

 

  

 

  

  

U.S. Treasury securities

$

172,885,459

$

$

Money market funds (1)

$

602,742

$

$

Liabilities

Derivative Warrant liability- Private warrants

$

$

$

424,940

(1)Includes cash balance held within the Trust Account of $1,264 at December 31, 2022.

Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. There were no transfers to/from Levels 1, 2, and 3 during the three and six months ended June 30, 2023 and 2022.

Level 1 assets include investments in U.S. government securities. The Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.

The fair value of the Private Placement Warrants was measured at fair value using a Black-Scholes model. The estimated fair value of the Private Placement Warrants is determined using Level 3 inputs. Inherent in a Black-Scholes model is assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s common stock that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

For the three and six months ended June 30, 2023, the Company recognized a loss in the unaudited condensed consolidated statements of operations resulting from a increase in fair value of the derivative warrant liability of approximately $1.8 million and $2.0 million, respectively, presented as change in fair value of derivative warrant liability in the accompanying unaudited condensed consolidated statements of operations. For the three and six months ended June 30, 2022, the Company recognized a gain in the unaudited condensed consolidated statements of operations resulting from a decrease in fair value of the derivative warrant liability of approximately $1.6 million and $4.3 million, respectively, presented as change in fair value of derivative warrant liability in the accompanying unaudited condensed consolidated statements of operations.

The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement dates:

    

June 30, 2023

    

December 31, 2022

Exercise price

$

11.50

$

11.50

Share price

$

10.33

$

9.95

Expected term (years)

5.17

5.40

Volatility

0.5

%

5.50

%

Risk-free rate

4.12

%

3.98

%

Probability of completion of Business Combination

50.00

%

10.00

%

Dividend yield (per share)

0.00

%

0.00

%

The change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs, for the three and six months ended June 30, 2023, is summarized below.

Derivative warrant liability at December 31, 2022

    

$

424,940

Change in fair value of derivative warrant liability

 

236,070

Derivative warrant liability at March 31, 2023

$

661,010

Change in fair value of derivative warrant liability

283,300

Derivative warrant liability at June 30, 2023

$

944,310

The change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs, for the three and six months ended June 30, 2022, is summarized below.

Derivative warrant liability at December 31, 2021

    

$

5,571,410

Change in fair value of derivative warrant liability

(2,691,270)

Derivative warrant liability at March 31, 2022

2,880,140

Change in fair value of derivative warrant liability

(1,605,330)

Derivative warrant liability at June 30, 2022

$

1,274,810

v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events  
Subsequent Events

Note 10—Subsequent Events

The Company evaluated subsequent events and transactions that occurred up to the date of these unaudited condensed consolidated financial statements were issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements.

v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Basis of Presentation and Summary of Significant Accounting Policies  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and pursuant to the rules and regulations of the SEC. Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these condensed financial statements as they are not required for interim financial statements under GAAP and the rules of the SEC. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the period presented. Operating results for the three and six months ended June 30, 2023, and since inception are not necessarily indicative of the results that may be expected through December 31, 2023, or any future period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2023.

Principles of Consolidation

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Emerging Growth Company

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of income and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June 30, 2023, and December 31, 2022.

Cash and investments Held in the Trust Account

Cash and investments Held in the Trust Account

The Company’s portfolio of investments is comprised of cash and U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. Gains and losses resulting from the change in fair value of these securities are included in income on investments held in the Trust Account in the accompanying condensed consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB Topic ASC 820, “Fair Value Measurements,” equals or approximates the carrying amounts represented in the condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liabilities.

Fair Value Measurements

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Derivative Warrant Liability

Derivative Warrant Liability

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company will evaluate its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

The Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the carrying value of the instruments to fair value at each reporting period until they are exercised. The fair value of the Private Placement Warrants as of June 30, 2023, and December 31, 2022, is determined using Black-Scholes option pricing model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Offering Costs Associated with the Initial Public Offering

Offering Costs Associated with the Initial Public Offering

Offering costs consist of legal, underwriting fees, accounting, and other costs incurred through the condensed consolidated balance sheet date that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liability will be expensed as incurred, presented as non-operating expenses in the condensed statements of operations. Offering costs associated with the Public Shares issued were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Common Stock Subject to Possible Redemption

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption (if any) is classified as liability instruments and is measured at fair value. Conditionally redeemable common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain

redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, June 30, 2023 and December 31, 2022, 6,083,500 and 17,161,500 shares of common stock subject to possible redemption at the redemption amount were presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed consolidated balance sheets, respectively.

Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering (including exercise of the over-allotment option), the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

Income Taxes

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2023 and December 31, 2022, the Company had full valuation allowance against the deferred tax assets.

ASC 740 prescribes a recognition threshold and a measurement attribute for the unaudited condensed consolidated financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2023 and December 31, 2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of June 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.

Net (Loss) Income per Share of Common Stock

Net (Loss) Income per Share of Common Stock

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net (loss) income per common stock is computed by dividing net (loss) income by the weighted average number of shares of common stock outstanding during the period.

The calculation of diluted net (loss) income per common stock does not consider the effect of the warrants issued in connection with the Initial Public Offering (including exercise of the over-allotment option) and the Private Placement to purchase an aggregate of 8,153,833 shares of common stock in the calculation of diluted (loss) income per common stock, because their exercise is contingent upon future events. As a result, diluted net (loss) income per common stock is the same as basic net (loss) income per common stock for the three and six months ended June 30, 2023 and 2022. Accretion associated with the redeemable common stock is excluded from earnings per share as the redemption value approximates fair value.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820, “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The ASU applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in this ASU are effective for the Company in fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the unaudited condensed consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.

v3.23.2
Common Stock Subject to Possible Redemption (Tables)
6 Months Ended
Jun. 30, 2023
Common Stock Subject to Possible Redemption  
Schedule of common stock subject to possible redemption

Common stock subject to possible redemption as of December 31, 2021

    

$

171,615,000

Plus:

 

Waiver of offering costs allocated to common stock subject to possible redemption

3,724,646

Less:

 

Adjustment for accretion of common stock subject to possible redemption amount

 

(2,175,524)

Common stock subject to possible redemption as of December 31, 2022

173,164,122

Plus:

Waiver of offering costs allocated to common stock subject to possible redemption

 

12,467

Adjustment for accretion of common stock subject to possible redemption amount

1,507,323

Common stock subject to possible redemption as of March 31, 2023

174,683,912

Plus:

Adjustment for accretion of common stock subject to possible redemption amount

1,408,829

Less:

Redemptions

(113,296,457)

Common stock subject to possible redemption as of June 30, 2023

$

62,796,284

v3.23.2
Fair Value of Measurements (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value of Measurements  
Schedule of assets and liabilities that are measured at fair value on a recurring basis

    

Quoted Prices in

    

Significant Other

Significant Other

June 30, 2023

Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

    

(Level 3)

Liabilities

Derivative Warrant liability- Private warrants

 

$

 

$

 

$

944,310

    

Quoted Prices in

    

Significant Other

Significant Other

December 31, 2022

Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

    

(Level 3)

Assets - Investments held in Trust Account (1)

 

  

 

  

  

U.S. Treasury securities

$

172,885,459

$

$

Money market funds (1)

$

602,742

$

$

Liabilities

Derivative Warrant liability- Private warrants

$

$

$

424,940

(1)Includes cash balance held within the Trust Account of $1,264 at December 31, 2022.
Schedule of quantitative information regarding Level 3 fair value measurements inputs at their measurement dates

    

June 30, 2023

    

December 31, 2022

Exercise price

$

11.50

$

11.50

Share price

$

10.33

$

9.95

Expected term (years)

5.17

5.40

Volatility

0.5

%

5.50

%

Risk-free rate

4.12

%

3.98

%

Probability of completion of Business Combination

50.00

%

10.00

%

Dividend yield (per share)

0.00

%

0.00

%

Schedule of change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs

Derivative warrant liability at December 31, 2022

    

$

424,940

Change in fair value of derivative warrant liability

 

236,070

Derivative warrant liability at March 31, 2023

$

661,010

Change in fair value of derivative warrant liability

283,300

Derivative warrant liability at June 30, 2023

$

944,310

Derivative warrant liability at December 31, 2021

    

$

5,571,410

Change in fair value of derivative warrant liability

(2,691,270)

Derivative warrant liability at March 31, 2022

2,880,140

Change in fair value of derivative warrant liability

(1,605,330)

Derivative warrant liability at June 30, 2022

$

1,274,810

v3.23.2
Description of Organization and Business Operations (Details)
6 Months Ended 12 Months Ended
May 22, 2023
USD ($)
$ / shares
shares
Jun. 02, 2021
USD ($)
$ / shares
shares
May 25, 2021
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
item
$ / shares
shares
Dec. 31, 2022
USD ($)
Description of Organization and Business Operations          
Condition for future business combination number of businesses minimum | item       1  
Share price (in dollars per unit) | $ / shares       $ 10.00  
Maximum number additional Units granted for underwriter to purchase at Initial Public Offering | shares       2,250,000  
Net proceeds of sale       $ 171,600,000  
Threshold minimum aggregate fair market value as a percentage of the net assets held in the Trust Account       80.00%  
Threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete Business Combination       50.00%  
Minimum net tangible assets upon consummation of Business Combination       $ 5,000,001  
Threshold percentage of public shares subject to redemption without Company's prior written consents       20  
Obligation to redeem public shares if entity does not complete a business combination (as a percent)       100.00%  
Maximum allowed dissolution expenses       $ 100,000  
Operating bank accounts       41,000  
Working capital       6,200,000  
Working Capital Loans outstanding       $ 416,710 $ 0
Redemption of exercised shares | shares 11,078,000     6,083,500  
Redemption of common stock $ 113,296,457     $ 113,296,457  
Sponsor          
Description of Organization and Business Operations          
Payments for investment of cash in Trust Account       25,000  
Repayment of promissory note - related party       $ 67,000  
Common Stock          
Description of Organization and Business Operations          
Redemption of exercised shares | shares 11,078,000        
Redemption price per share | $ / shares $ 10.227        
Redemption of common stock $ 113,300,000        
Common Stock | Public Warrants          
Description of Organization and Business Operations          
Redemption price per share | $ / shares $ 0.03        
Redemption of common stock $ 165,000        
Initial Public Offering          
Description of Organization and Business Operations          
Number of units sold in Initial Public Offering (in shares) | shares     15,000,000    
Share price (in dollars per unit) | $ / shares     $ 10.00 $ 10.00  
Gross proceeds from Initial Public Offering     $ 150,000,000.0    
Offering costs     8,800,000    
Deferred underwriting commissions     $ 5,300,000    
Purchase price, per unit | $ / shares       $ 10.00  
Initial Public Offering | Common Stock          
Description of Organization and Business Operations          
Number of units sold in Initial Public Offering (in shares) | shares       8,153,833  
Redemption of exercised shares | shares       17,161,500  
Private Placement | Private Placement Warrants          
Description of Organization and Business Operations          
Sale of Private Placement Warrants (in shares) | shares     4,433,333    
Price of warrant (in dollars per warrant) | $ / shares     $ 1.50    
Proceeds from sale of Private Placement Warrants     $ 6,700,000    
Private Placement | Additional Private Placement Warrants          
Description of Organization and Business Operations          
Price of warrant (in dollars per warrant) | $ / shares   $ 1.50      
Proceeds from sale of Private Placement Warrants   $ 432,000      
Additional units sold of shares | shares   288,200      
Over-allotment option          
Description of Organization and Business Operations          
Number of units sold in Initial Public Offering (in shares) | shares   2,161,500      
Gross proceeds from Initial Public Offering   $ 21,600,000      
Offering costs   1,200,000      
Period of option to purchase additional units for underwriter     45 days    
Maximum number additional Units granted for underwriter to purchase at Initial Public Offering | shares     2,250,000    
Deferred underwriting fess   $ 757,000      
v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)
6 Months Ended
May 25, 2021
Jun. 30, 2023
May 22, 2023
Dec. 31, 2022
Basis of Presentation and Summary of Significant Accounting Policies        
Cash equivalents   $ 0   $ 0
Unrecognized tax benefits   0   0
Unrecognized tax benefits accrued for interest and penalties   $ 0   $ 0
Common stock shares subject to possible redemption   6,083,500 11,078,000  
Common Stock        
Basis of Presentation and Summary of Significant Accounting Policies        
Common stock shares subject to possible redemption     11,078,000  
Initial Public Offering        
Basis of Presentation and Summary of Significant Accounting Policies        
Number of units sold in Initial Public Offering (in shares) 15,000,000      
Initial Public Offering | Common Stock        
Basis of Presentation and Summary of Significant Accounting Policies        
Number of units sold in Initial Public Offering (in shares)   8,153,833    
Common stock shares subject to possible redemption   17,161,500    
v3.23.2
Initial Public Offering (Details) - USD ($)
6 Months Ended
Jun. 02, 2021
May 25, 2021
Jun. 30, 2023
May 16, 2022
Initial Public Offering        
Maximum number additional Units granted for underwriter to purchase at Initial Public Offering     2,250,000  
Share price (in dollars per unit)     $ 10.00  
Deferred underwriting fee waived       $ 3,900,000
Initial Public Offering        
Initial Public Offering        
Number of units sold in Initial Public Offering (in shares)   15,000,000    
Number of shares in a unit   1    
Number of shares issuable per warrant   1    
Proceeds from issuance initial public offering   $ 150,000,000.0    
Share price (in dollars per unit)   $ 10.00 $ 10.00  
Offering costs   $ 8,800,000    
Deferred underwriting commissions   $ 5,300,000    
Initial Public Offering | Public Warrants        
Initial Public Offering        
Number of warrants in a unit   0.20    
Exercise price of warrants   $ 11.50    
Over-allotment option        
Initial Public Offering        
Number of units sold in Initial Public Offering (in shares) 2,161,500      
Maximum number additional Units granted for underwriter to purchase at Initial Public Offering   2,250,000    
Proceeds from issuance initial public offering $ 21,600,000      
Offering costs 1,200,000      
Deferred underwriting fess $ 757,000      
v3.23.2
Related Party Transactions - Founder Shares (Details)
6 Months Ended
Jul. 14, 2021
shares
Jun. 02, 2021
USD ($)
$ / shares
shares
May 25, 2021
USD ($)
$ / shares
shares
Apr. 08, 2021
shares
Feb. 13, 2021
USD ($)
shares
Jun. 30, 2023
D
$ / shares
Private Placement | Private Placement Warrants            
Related Party Transaction            
Sale of Private Placement Warrants (in shares)     4,433,333      
Price of warrant (in dollars per warrant) | $ / shares     $ 1.50      
Proceeds from sale of Private Placement Warrants | $     $ 6,700,000      
Private Placement | Additional Private Placement Warrants            
Related Party Transaction            
Price of warrant (in dollars per warrant) | $ / shares   $ 1.50        
Proceeds from sale of Private Placement Warrants | $   $ 432,000        
Additional units sold of shares   288,200        
Private placements | Sponsor            
Related Party Transaction            
Price of warrant (in dollars per warrant) | $ / shares   $ 11.50        
Number of shares issuable per warrant   1        
Private placements | Sponsor | Private Placement            
Related Party Transaction            
Price of warrant (in dollars per warrant) | $ / shares     $ 1.50      
Proceeds from sale of Private Placement Warrants | $     $ 6,700,000      
Private placements | Sponsor | Private placement two            
Related Party Transaction            
Sale of Private Placement Warrants (in shares)     4,433,333      
Price of warrant (in dollars per warrant) | $ / shares   $ 1.50        
Proceeds from sale of Private Placement Warrants | $   $ 400,000        
Additional units sold of shares   288,200        
Founder Shares | Sponsor            
Related Party Transaction            
Aggregate purchase price | $         $ 25,000  
Number of shares issued         4,312,500  
Shares subject to forfeiture       562,500    
Number of shares forfeited   22,125        
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders       20.00%    
Common stock outstanding (in shares)   4,290,375   4,252,500    
Restrictions on transfer period of time after business combination completion           1 year
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares           $ 12.00
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D           20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D           30
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences           120 days
Founder Shares | Sponsor | Independent directors            
Related Party Transaction            
Number of shares transferred       20,000    
Founder Shares | Sponsor | Alexandra Lebenthal            
Related Party Transaction            
Number of shares transferred 20,000          
Related Party Loans | Sponsor            
Related Party Transaction            
Price of warrant (in dollars per warrant) | $ / shares           $ 1.50
v3.23.2
Related Party Transactions - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
May 15, 2023
Dec. 21, 2022
May 06, 2022
May 20, 2021
Jan. 29, 2021
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Related Party Transactions                    
Working Capital Loans               $ 416,710 $ 0  
Outstanding balance for services           $ 32,809   32,809 0  
Borrowings under the working capital loans                   $ 0
Convertible promissory note - related party           416,710   416,710 0  
Warrants                    
Related Party Transactions                    
Quantity of warrants issued 1,000,000                  
Administrative Services Agreement                    
Related Party Transactions                    
Borrowings under the working capital loans           0   0 0  
Other Related Party Transactions                    
Related Party Transactions                    
Outstanding balance of related party note           6,652   6,652 $ 0  
Related party | Administrative Services Agreement | G-SPAC Management LLC [Member]                    
Related Party Transactions                    
Expenses per month               90,000    
Administrative fees expense per month             $ 45,000      
Incurred expenses       $ 15,000            
Related party | Other Related Party Transactions                    
Related Party Transactions                    
Expenses           $ 81,000   $ 170,000    
Sponsor [Member] | Convertible Promissory Note                    
Related Party Transactions                    
Price of warrant (in dollars per warrant) $ 1.50                  
Principal amount of promissory note $ 1,500,000                  
Sponsor [Member] | Related Party Loans                    
Related Party Transactions                    
Price of warrant (in dollars per warrant)           $ 1.50   $ 1.50    
Proceeds held in trust account used to repay working capital loans               $ 0    
Loan conversion agreement warrant           $ 1,500,000   $ 1,500,000    
Maximum borrowing capacity of related party promissory note         $ 150,000          
Proceeds from note payable to related party         $ 70,000          
CFO | Other Related Party Transactions                    
Related Party Transactions                    
Compensation expense per month   $ 16,667                
Officer [Member] | Other Related Party Transactions                    
Related Party Transactions                    
Compensation expense per month     $ 6,000              
v3.23.2
Commitments and Contingencies (Details)
6 Months Ended
May 22, 2023
USD ($)
shares
May 08, 2023
USD ($)
May 16, 2022
USD ($)
Jun. 02, 2021
USD ($)
shares
May 25, 2021
USD ($)
shares
Jun. 30, 2023
USD ($)
item
D
$ / shares
shares
Dec. 31, 2022
shares
Commitments and Contingencies              
Maximum number of demands for registration of securities | item           3  
Underwriting grants option days | D           45  
Maximum number of purchase additional units less underwriting discounts and commissions | shares           2,250,000  
Underwriting discount per unit | $ / shares           $ 0.20  
Underwriting discount paid amount           $ 3,400,000  
Deferred fee per unit | $ / shares           $ 0.35  
Aggregate deferred underwriting commission fee payable           $ 6,000,000.0  
Gain on settlement of deferred underwriting commissions     $ 3,900,000        
Payments to suppliers           $ 4,500  
Redemption of exercised shares | shares 11,078,000         6,083,500  
Redemption of common stock $ 113,296,457         $ 113,296,457  
Vendor Agreement              
Commitments and Contingencies              
Advisory fee payable in cash   $ 2,000,000          
Advisory fee payable by kind   2,000,000          
Minimum adequacy of capital raised in business combination   20,000,000          
Minimum adequacy of capital raised in business combination by cash   2,500,000          
Minimum adequacy of capital raised in business combination by kind   2,000,000          
Minimum adequacy of capital raised in business combination   20,000,000          
Maximum adequacy of capital raised in business combination   40,000,000          
Maximum adequacy of capital raised in business combination by cash   4,000,000          
Maximum adequacy of capital raised in business combination by kind   1,000,000          
Reimbursement of vendor expenses   200,000          
Vendor Agreement | Minimum              
Commitments and Contingencies              
Adequacy of capital raised in business combination by kind   40,000,000          
Adequacy of capital raised in business combination   5,000,000          
Vendor Agreement | Maximum              
Commitments and Contingencies              
Adequacy of capital raised in business combination by kind   50,000,000          
Adequacy of capital raised in business combination   $ 50,000,000          
Common stock subject to possible redemption              
Commitments and Contingencies              
Common stock carrying value           3,700,000  
Gain from extinguishment of deferred underwriting commissions allocated to derivative warrant liability           $ 180,000  
Redemption of exercised shares | shares           6,083,500 17,161,500
Initial Public Offering              
Commitments and Contingencies              
Underwriting discount paid amount         $ 3,000,000.0    
Aggregate deferred underwriting commission fee payable         $ 5,250,000    
Over-allotment option              
Commitments and Contingencies              
Maximum number of purchase additional units less underwriting discounts and commissions | shares         2,250,000    
Number of additional purchased units that exercised the over-allotment option | shares       2,161,500      
Underwriting discount paid amount       $ 400,000      
Aggregate deferred underwriting commission fee payable       $ 800,000      
v3.23.2
Common Stock Subject to Possible Redemption (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
May 22, 2023
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Dec. 31, 2022
Common Stock Subject to Possible Redemption            
Adjustment for accretion of common stock subject to possible redemption amount   $ (1,408,829) $ (1,507,323) $ 3,724,646    
Redemptions $ (113,296,457)       $ (113,296,457)  
Common Stock Subject To Possible Redemption            
Common Stock Subject to Possible Redemption            
Common stock subject to possible redemption, Beginning balance   174,683,912 173,164,122   173,164,122 $ 171,615,000
Waiver of offering costs allocated to common stock subject to possible redemption     12,467     3,724,646
Adjustment for accretion of common stock subject to possible redemption amount   1,408,829 1,507,323     (2,175,524)
Redemptions   (113,296,457)        
Common stock subject to possible redemption, Ending balance   $ 62,796,284 $ 174,683,912   $ 62,796,284 $ 173,164,122
v3.23.2
Common Stock Subject to Possible Redemption - The condensed balance sheet (Details)
Jun. 30, 2023
Vote
$ / shares
shares
May 22, 2023
shares
Dec. 31, 2022
$ / shares
shares
Common Stock Subject to Possible Redemption      
Common stock, shares authorized 400,000,000   400,000,000
Common stock, par value (in dollars per share) | $ / shares $ 0.0001   $ 0.0001
Common stock, votes per share | Vote 1    
Common stock shares outstanding including shares subject to possible redemption 10,373,875   21,451,875
Common stock shares subject to possible redemption 6,083,500 11,078,000  
Common stock subject to possible redemption      
Common Stock Subject to Possible Redemption      
Common stock shares subject to possible redemption 6,083,500   17,161,500
v3.23.2
Stockholders' Deficit - Preferred stock (Details) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Stockholders' Deficit    
Preferred stock authorized (in shares) 1,000,000 1,000,000
Preferred stock, par value, (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock issued (in shares) 0 0
Preferred stock outstanding (in shares) 0 0
v3.23.2
Stockholders' Deficit - Common Stock (Details)
Jun. 30, 2023
Vote
$ / shares
shares
May 22, 2023
shares
Dec. 31, 2022
$ / shares
shares
Stockholders' Deficit      
Common stock authorized (in shares) 400,000,000   400,000,000
Common stock, par value (in dollars per share) | $ / shares $ 0.0001   $ 0.0001
Common stock, votes per share | Vote 1    
Redemption of exercised shares 6,083,500 11,078,000  
Common stock subject to possible redemption      
Stockholders' Deficit      
Redemption of exercised shares 6,083,500   17,161,500
Common stock not subject to possible redemption      
Stockholders' Deficit      
Common stock authorized (in shares) 400,000,000   400,000,000
Common stock, par value (in dollars per share) | $ / shares $ 0.0001   $ 0.0001
Common stock issued (in shares) 4,290,375   4,290,375
Common stock outstanding (in shares) 4,290,375   4,290,375
v3.23.2
Warrants (Details)
6 Months Ended
Jun. 30, 2023
D
$ / shares
shares
Dec. 31, 2022
shares
Public Warrants    
Warrants    
Warrants outstanding | shares 3,432,300  
Warrant exercise period condition one 30 days  
Maximum period after business combination in which to file registration statement 20 days  
Period of time within which registration statement is expected to become effective 60 days  
Redemption price per public warrant (in dollars per share) $ 11.50  
Public Warrants expiration term 5 years  
Share price trigger used to measure dilution of warrant. $ 9.20  
Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant 60  
Threshold trading days for redemption of public warrants | D 20  
Warrant redemption price adjustment multiple 115  
Warrant redemption condition minimum share price $ 18.00  
Warrant exercise price adjustment multiple 180  
Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00    
Warrants    
Redemption price per public warrant (in dollars per share) $ 0.01  
Threshold trading days for redemption of public warrants | D 20  
Warrant redemption condition minimum share price $ 18.00  
Minimum threshold written notice period for redemption of public warrants 30 days  
Threshold consecutive trading days for redemption of public warrants | D 30  
Private Placement Warrants    
Warrants    
Warrants outstanding | shares   4,721,533
v3.23.2
Fair Value of Measurements - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Fair value of assets transferred from level 1 to 2 $ 0 $ 0 $ 0 $ 0  
Fair value of assets transferred from level 2 to 1 0 0 0 0  
Fair value assets transferred into (out of) level 3 0 0 0 0  
Increase decrease in fair value of derivative warrant liabilities 283,300 $ (1,605,330) 519,370 $ (4,296,600)  
Assets Held-in-trust, Noncurrent 63,529,895   63,529,895   $ 173,488,201
Cash withdrawn from Trust Account in connection with redemption     113,296,457    
Withdrew for franchise and income taxes from trust account     381,239   568,642
Increase in fair value of derivative warrant liability 1,800,000   2,000,000.0    
Demand deposit account          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Assets Held-in-trust, Noncurrent $ 0   $ 0   602,742
U.S. Treasury Securities          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Assets Held-in-trust, Noncurrent         $ 172,885,459
v3.23.2
Fair Value of Measurements - Assets and liabilities that are measured at fair value on a recurring basis (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Assets - Investments held in Trust Account:    
Marketable securities held in Trust Account $ 63,529,895 $ 173,488,201
Liabilities    
Derivative Warrant liability 944,310 424,940
cash balance held Trust Account   1,264
Demand deposit account    
Assets - Investments held in Trust Account:    
Marketable securities held in Trust Account 0 602,742
Level 1 | U.S. Treasury Securities    
Assets - Investments held in Trust Account:    
Marketable securities held in Trust Account   172,885,459
Level 1 | Money market funds    
Assets - Investments held in Trust Account:    
Marketable securities held in Trust Account   602,742
Level 3 | Private Placement Warrants    
Liabilities    
Derivative Warrant liability $ 944,310 $ 424,940
v3.23.2
Fair Value of Measurements - Quantitative information regarding Level 3 fair value measurements inputs (Details) - Level 3
Jun. 30, 2023
Y
$ / shares
Dec. 31, 2022
$ / shares
Y
Exercise price    
Fair Value of Measurements    
Measurement input 11.50 11.50
Share price    
Fair Value of Measurements    
Measurement input 10.33 9.95
Expected term (years)    
Fair Value of Measurements    
Measurement input | Y 5.17 5.40
Volatility    
Fair Value of Measurements    
Measurement input 0.005 0.0550
Risk-free rate    
Fair Value of Measurements    
Measurement input 0.0412 0.0398
Probability of completion of Business Combination    
Fair Value of Measurements    
Measurement input 0.5000 0.1000
Dividend yield (per share)    
Fair Value of Measurements    
Measurement input 0.0000 0.0000
v3.23.2
Fair Value of Measurements - Change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs (Details) - Level 3 - USD ($)
3 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs        
Derivative warrant liability, beginning balance $ 661,010 $ 424,940 $ 2,880,140 $ 5,571,410
Change in fair value of derivative warrant liability 283,300 236,070 (1,605,330) (2,691,270)
Derivative warrant liability, ending balance $ 944,310 $ 661,010 $ 1,274,810 $ 2,880,140

Graf Acquisition Corp IV (NYSE:GFOR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Graf Acquisition Corp IV Charts.
Graf Acquisition Corp IV (NYSE:GFOR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Graf Acquisition Corp IV Charts.